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ABSTRACT
CROSS-SECTIONAL AND LONGITUDINAL EFFECTS OF GLYCEMIC STATUS
ON BODY COMPOSITION, BONE, AND LIPID PROFILE IN MEN AGED 20 TO 66
YEARS: A POPULATION-BASED STUDY
KHALEAL ALMUSAYLIM
2019
Pre-diabetes and type 2 diabetes (T2D) are significant public health challenges in the
United States. Pre-diabetes and T2D are a multi-factorial disease characterized by genetic
or environmental factors or a combination of both. There has been an upward trend over
time in the prevalence of both pre-diabetes and T2D. Few epidemiological studies exist
regarding the effect of baseline glycemic status on changes in body composition, bone
health, and lipid profiles. To fill this critical gap, the purpose of this research was to
examine both cross-sectional and longitudinal changes in glycemic status with changes in
body composition, bone mass and density, and lipid profile and cardiovascular risk ratios
in men aged 20 to 66 years.
This dissertation uses data from the South Dakota Rural Bone Health Study, a
population-based longitudinal study designed to investigate the impact of lifestyle factors
on bone and body composition. Findings from this study provide insight into the adverse
effect of changes in glycemic status on total and regional body composition and bone
health. Creating prevention strategies targeted at individuals affected by, or at risk of,
pre-diabetes and T2D, such as promoting a healthy diet, physical activity, and weight loss
may reverse the unfavorable effects of pre-diabetes and T2D.
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CHAPTER 1: Introduction

Pre-diabetes
Pre-diabetes is a hyperglycemic state, which a blood glucose concentration is
greater than normal and lower than type 2 diabetes (T2D) thresholds. Pre-diabetes occurs
in response to defects in insulin sensitivity and secretion as a result of impaired β-cell
function and insulin resistance [1]. The current diagnostic criteria from the American
Diabetes Association (ADA) define pre-diabetes as impaired fasting blood glucose of 100
to 125 mg/dL, or impaired glucose tolerance of 140 to 199 mg/dL, or hemoglobin A1c
(HbA1c) of 5.7 to 6.4% [2]. Different criteria used to diagnose pre-diabetes result in
heterogeneity within subjects. Individuals with impaired fasting glucose seem to have
moderate insulin resistance in the liver and adipose tissue, impaired first-phase insulin
secretion in the pancreas, and normal or nearly normal insulin sensitivity in the muscle,
whereas those with impaired glucose tolerance seem to have moderate to severe muscle
insulin resistance, insulin secretory defect, and nearly normal hepatic insulin sensitivity
[3,4].
The number of adults with pre-diabetes the United States (US) increased from 79
million in 2010 to 84.1 million in 2015 (20% annually) [5,6]. The prevalence of prediabetes in the US among adults aged ≥ 18 years was 33.9% in 2015. Only11.6% of prediabetics were aware of their condition. The prevalence of pre-diabetes varies across age
and sex. Men (36.9%) and older adults aged ≥ 65 years (48.3%) have higher pre-diabetes
than women (31.1%) and young (23.7%) and middle-aged (40.9%) adults [6]. Pre-
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diabetes is associated with cardiovascular disease [7,8] and coronary heart disease [9].
Pre-diabetes places an economic burden on diagnosed individuals and health care
services. The total average medical cost per case was $510 per year, and the total medical
and nonmedical costs were $43, 910 million in 2012 [10].
The ADA recommends lifestyle modifications, including 7% loss of initial body
weight, caloric restriction, and performing 150 minutes moderate physical activity per
week, as a key prevention strategy for T2D. Achievement and maintenance of lifestyle
modifications play a pivotal role in stopping the conversion from pre-diabetes to T2D
[11]. The pre-diabetic state may last for several years ranging from one year to six years
before reverting to normoglycemia or progressing to T2D. In the US, intervention studies
reported that lifestyle changes result in 40% reversion from pre-diabetes to
normoglycemia over three years [12]. Conversion from pre-diabetes to T2D was 31.5%
within three years in adults without lifestyle modifications [13].
Type 2 Diabetes
T2D has become a major concern in the US and is characterized by
hyperglycemia due to defects of insulin secretion and action. T2D is caused by a
combination of insulin resistance and β-cell dysfunction [14]. Accumulation of ectopic
fat in the liver and muscle as a consequence of greater intake of total energy than energy
expenditure contributes to insulin resistance in response to a reduction in fat oxidation in
mitochondria [15]. Fat deposition in the pancreas may lead to the impairment in β-cell
function [16]. The current ADA diagnostic criteria for T2D are as follows: impaired
fasting blood glucose ≥ 126 mg/d, or 2-h plasma glucose ≥ 200 mg/dL, or HbA1c ≥
6.5%, or random plasma glucose ≥ 200 mg/dL [2]. The age-adjusted prevalence of T2D
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among US adults aged ≥ 20 years was 8.2% in 2016-2017. The prevalence of T2D has
increased due to the aging of the US population and increased rates of obesity. In 20162017, the prevalence of T2D was 11.1% and 18.2% of American adults aged 45 to 64
years and 65 years, respectively. The 2016-2017 National Health Interview Survey
reported 6.7% of overweight and 14.1% of obese adults had T2D [17].
T2D adults suffer microvascular and macrovascular complications [18] that are a
major cause of morbidity and mortality [19]. T2D imposes a large financial burden on
patients, quality of life, and healthcare system costing millions of dollars. In 2007, the US
national economic burden of T2D was estimated at $9,677 per case, $105.7 million
dollars for medical cost and $53.8 million dollars for nonmedical cost [20]. T2D
management in each care setting is crucial to reducing the economic burden. Lifestyle
intervention studies have consistently reported that changes in lifestyle behaviors (weight
reduction, healthy eating plus increasing physical activity) are accompanied by a 58%
risk reduction in T2D [12,21]. These intervention studies provide clear empirical
evidence of the role of achieving health behaviors goals in the prevention of T2D.
Dysglycemia and Body Composition
Chronic inflammation, oxidative stress, and abnormality of lipid metabolism
promote insulin resistance [22,23] that precedes the onset of pre-diabetes and
T2D. Insulin resistance is identified as a risk factor affecting total and regional body
composition in middle-aged and older men [24,25]. Therefore, alteration in total body
(TB) composition and its distribution can occur early in the upper and lower extremities
before the development of dysglycemia (pre-diabetes or T2D). Insulin-resistant men are
more likely to lose TB and appendicular lean mass (LM) [24,25] and less likely to gain
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TB and trunk fat mass (FM) [25]. Disturbance in the balance between anabolism and
catabolism of muscle protein and increased rates of lipolysis contribute to skeletal muscle
loss and decreased fat gain in insulin-resistant men [25,26]. Since insulin resistance
directly affects skeletal muscle and adipose tissue, alterations in body composition is
further augmented by dysglycemia.
The evidence, however, to support the association of glycemic status with total
and regional FM and LM remains inconclusive. Case-control and cross-sectional studies
of middle-aged and older adults have shown positive, negative or no association of
glycemic status with absolute or percent TB and regional FM and LM as presented in
Tables 1.1 and 1.2 [27-34]. A possible explanation of greater FM of upper and lower
limbs in pre-diabetic and T2D individuals is an accumulation of intra-abdominal and
intermuscular adipose tissue. T2D subjects had greater visceral and intermuscular adipose
tissues than normoglycemic stbjucts, suggesting that subjects with T2D had a larger
porportion of visceral and intermuscular adipose tiusses to TB FM. Visceral adipose
tissue and adipose tissue interspread wihin skeletal muscle lead to more accumlation of
ectopic fat [35,36].
Only three longitudinal studies have examined the association of baseline
glycemic status with absolute changes in TB FM and its compartments and these studies
have shown mixed findings (Table 1.1) [37-40]. Pre-diabetic young adults slightly gained
TB FM over time compared to their normoglycemic counterparts [37]. No changes or
small increases in TB and trunk FM were seen in middle-aged and older adults with T2D
[38-40]. The underlying mechanism for lower rates of TB and trunk FM gain in
dysglycemic individuals may be due to greater rises in energy expenditure and fat
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oxidation leading to attenuation of FM gain [37]. Prospective cohort studies have
produced contradictory findings with respect to the relationship of baseline glycemic
status to changes in TB LM and its distribution (Table 1.2) [37-42]. Dysglycemia appears
to accelerate the loss of absolute and percent TB, appendicular, and leg LM [39-41]
through various mechanistic pathways including insulin resistance, hyperglycemia,
dysfunctional mitochondria, chronic inflammation, oxidative stress, and fat infiltration
into the muscle [43].
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Table 1.1. Baseline and changes in total and regional fat mass (FM) by glycemic status.
Participants
(Follow-up
Study name
time)
Case-control studies
Community30 Swedish men
dwelling
aged 48-49 years,
cohort [27]
17 NG and 13
T2D
Look AHEAD
102 US adults
trial [28]
55-60 years, 35
Non-T2D and 67
T2D
Communitydwelling
cohort [29]

92 Dutch men
aged 69-72 years,
32 NG and 60
T2D

Cross-sectional studies
Outpatient
142 Polish men
clinic for
aged 62-70 years,
GMD [30]
58 NG and 84
pre-diabetic
NHANES [31]

1781 US men
aged 51-78 years,
1223 NG and
558 pre-diabetic

Diagnosis of
dysglycemia

Covariates

FM
measures

Findings

OGTT

Matched by
age, height, and
BMI

TB FM
Trunk FM

No difference between groups
Greater in T2D group than in NG group

FBG,
OGTT, selfreported, and
drug use

Age, sex,
ethnicity, site,
height, and TB
FM for trunk
and leg FM
Age, BMI,
FBG, HDL,
BCAA, protein
intake, and
physical activity

TB FM
Trunk FM

No difference between groups
Greater in T2D group than in Non-T2D
group
Lower in T2D group than in Non-T2D
group
No difference between groups

OGTT

FBG, OGTT,
and HbA1c

Leg FM
TB FM

TB FM
Trunk FM
Leg FM

FBG

Look AHEAD
trial [32]

1557 US adults
aged 55-59 years,
242 NG and
1315 T2D

FBG, OGTT,
self-reported,
and drug use

KSOS [33]

370 Korean men
aged 48-69 years,
152 NG and 218
T2D

FBG and
HbA1c

NHANES [31]

1353 men
aged51-75 years,
1223 NG and
130 T2D

FBG

Age, BMI,
ethnicity,
alcohol intake,
smoking, and
physical activity
Age, sex,
ethnicity, site,
height, and
weight for TB
FM
Age, sex,
ethnicity, site,
height, and TB
FM for trunk
and leg FM
Age, BMI,
physical
activity,
smoking,
alcohol intake,
antihypertensive
agent, lipid
lowering agent,
systolic and
diastolic blood
pressure, TC,
HDL, TG, and
FBG.
Age, BMI,
ethnicity,
alcohol intake,
smoking, and
physical activity

TB FM
Trunk FM
Appendicular
FM
TB FM
Trunk FM
Leg FM

Greater in pre-diabetic group than in NG
group
No difference between groups
No difference between groups
Greater in pre-diabetic group than in NG
group
Greater in pre-diabetic group than in NG
group
No difference among groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group
Lower in T2D group than in NG group

TB FM

Greater in T2D group than in NG group

TB FM
Trunk FM
Appendicular
FM

No difference between groups
Greater in T2D group than in NG group
No difference between groups
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Table 1.1. Baseline and changes in total and regional fat mass (FM) by glycemic status –
continued.
Participants
(Follow-up
time)

Study name
Prospective studies
Respiratory
122 Native
chamber study
American adults
[37]
aged 20-31, 101
NG and 21 prediabetic
(Over 5 years)
Health ABC
2449 US adults
Study [38]
aged 71-77 years,
2047 NG and
402 T2D
(Over 6 years)
Randomized trial studies
Look AHEAD
422 US men
trial [39,40]
aged 52-66 years,
220 T2D in DSE
and 202 T2D in
ILI
(Over 8 years)

Diagnosis of
dysglycemia

Covariates

FM
measures

Findings

FBG and
OGTT

Age, sex, and
baseline body
weight.

TB FM

Slight gain in pre-diabetic group in contrast to NG
group

FBG, OGTT,
HbA1c, selfreported, and
drug use

Age, sex,
ethnicity, site,
BMI, weight
loss intention,
and change in
body weight.

TB FM
Trunk FM
Appendic
ular FM

No difference between groups
Slight gain in T2D group in contrast to NG group
No difference between groups

FBG, OGTT,
self-reported,
and drug use

Age, clinic,
TB FM
Slight gain from baseline within the DSE group
Trunk FM No change from baseline within the DSE group
ethnicity,
HbA1c, time,
Leg FM
No change from baseline within the DSE group
and baseline
body
composition
measure
Abrreviation: GMD, glucose metabolism disorder; NHANES, the National Health and Nutrition Examination Survey; KSOS, the
Korean Sarcopenic Obesity Study; Health ABC Study, the Health, Aging, and Body composition Study; NG, normoglycemic, T2D,
type 2 diabetic; DSE, diabetes support and education; ILI, intensive lifestyle intervention; OGTT, oral glucose tolerance test; FBG,
fasting blood glucose; HbA1c, hemoglobin A1c; BMI, body mass index; TB FM, total body fat mass; HDL, high-density lipoprotein
cholesterol; BCAA, branched-chain amino acid; TC, total cholesterol; and TG, triglyceride.
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Table 1.2. Baseline and changes in total and regional lean mass (LM) by glycemic status.
Participants
(Follow-up
Study name
time)
Case-control studies
Look AHEAD
102 US adults
trial [28]
aged 47-67 years,
35 Non-T2D and
67 T2D

Communitydwelling
cohort [29]

92 Dutch men
aged 69-72 years,
32 NG and 60
T2D

Cross-sectional studies
NHANES [34] 2529 US men
aged 61-67 years,
1283 NG and
1246 pre-diabetic

Outpatient
clinic for
GMD [30]

Diagnosis of
dysglycemia
FBG, OGTT,
self-reported,
and drug use

OGTT

HbA1c

142 Polish men
aged 62-70 years,
58 NG and 84
pre-diabetic
1781 US men
aged 51-78 years,
1223 NG and
558 pre-diabetic

FBG, OGTT,
and HbA1c

Look AHEAD
trial [32]

1557 US adults
aged 45-76 years,
242 NG and
1315 T2D

FBG,
OGTT, selfreported, and
drug use

KSOS [33]

370 Korean men
aged 48-69, 152
NG and 218 T2D

FBG and
HbA1c

NHANES [31]

FBG

Covariates
Age, sex,
ethnicity, site,
height, and TB
FM except for
TB FM as an
outcome
measure
Age, BMI,
FBG, HDL,
BCAA, protein
intake, and
physical activity
Age, height,
ethnicity,
education,
smoking,
physical
activity, CRP,
CHD, PAD,
arthritis,
neuropathy, hip
fracture, lowerlimb
amputation,
cancer, and
COPD.

Age, BMI,
ethnicity,
alcohol intake,
smoking, and
physical activity
Age, sex,
ethnicity, site,
height, and
weight for TB
LM
Age, sex,
ethnicity, site,
height, and TB
LM for trunk
and leg LM
Age, BMI,
physical
activity,
smoking,
alcohol intake,
antihypertensive
agent, lipid
lowering agent,
systolic and
diastolic blood
pressure, TC,
HDL, TG, and
FBG.

LM
measures

Findings

TB LM

No difference between groups

TB LM
Appendicul
ar LM

No difference between groups
Greater in NG group than in pre-diabetic group

%TB LM
%Trunk
LM
%Appendic
ular LM

Lower in pre-diabetic group than in NG group
Lower in pre-diabetic group than in NG group

TB LM
Trunk LM
Leg LM

Greater in NG group than in pre-diabetic group
No difference between groups
No difference between groups

TB LM
Trunk LM
Appendicul
ar LM

No difference between groups
No difference between groups
No difference among groups

TB LM
Trunk LM
Leg LM

Greater in T2D group than in NG group
Greater in T2D group than in NG group
Lower in T2D group than in NG group

TB LM
Appendicul
ar LM

Lower in group T2D than in NG group
No difference between groups

Lower in pre-diabetic group than in NG group
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Table 1.2. Baseline and changes in total and regional lean mass (LM) by glycemic status
– continued.

Study name
NHANES [34]

NHANES [31]

Participants
(Follow-up
time)
1418 US men
aged 61-65 years,
1283 NG and
135 T2D

1353 US men
aged 51-75 years,
1223 NG and
130 T2D

Prospective studies
MrOS [41]
3256 US men
aged 67-78 years,
1853 NG and
1403 pre-diabetic
(Over 4.6 years)

Respiratory
chamber study
[37]

Health ABC
Study [38]

122 Native
American adults
aged 20-31years,
101 NG and 21
pre-diabetic
(Over 5 years)
2449 US adults
aged 71-77 years,
2047 NG and
402 T2D
(Over 6 years)

Diagnosis of
dysglycemia
Self-reported
and HbA1c

FBG

FBG, selfreported, and
drug use

FBG and
OGTT

FBG, OGTT,
HbA1c, selfreported, and
drug use

Covariates
Age, height,
ethnicity,
education,
smoking,
physical
activity, CRP,
CHD, PAD,
arthritis,
neuropathy, hip
fracture, lowerlimb
amputation,
cancer, and
COPD.
Age, BMI,
ethnicity,
alcohol intake,
smoking, and
physical activity

LM
measures
%TB LM
%Trunk
LM
%Appendic
ular LM

Findings
Lower in T2D group than in NG group
Lower in T2D group than in NG group
Lower in T2D group than in NG group

TB LM
Trunk LM
Appendicul
ar LM

No difference among groups
No difference among groups
No difference among groups

Age, ethnicity,
clinic site, selfrated health,
cardiac disease,
hypertension,
dyslipidemia,
education,
physical
activity, and
baseline TB FM
for TB LM as
an outcome
measure and TB
LM for
appendicular
LM as an
outcome
measure
Age, sex, and
baseline body
weight.

%TB LM
%Appendic
ular LM

No difference among groups
Slight decline in pre-diabetic group in contrast to
NG group

TB LM

No difference between groups

Age, sex,
ethnicity, site,
BMI, weight
loss intention,
and change in
body weight.

TB LM
Trunk LM
Appendicul
ar LM

No difference between groups
Slight gain in T2D group in contrast to NG group
No difference between groups
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Table 1.2. Baseline and changes in total and regional lean mass (LM) by glycemic status
– continued.

Study name
MrOS [41]

BLSA [42]

Participants
(Follow-up
time)
1964 US men
aged 67-78 years,
1853 NG and
111 T2D*
(3.5 years)

984 US adults
aged 44-79 years,
663 Non-T2D
and 321 T2D
(7.5 years)

Randomized trial studies
Look AHEAD
422 T2D US men
trial [39,40]
aged 52-66 years,
220 T2D in DSE
and 202 T2D in
ILI
(Over 8 years)

Diagnosis of
dysglycemia
FBG, selfreported, and
drug use

HbA1c

FBG, OGTT,
self-reported,
and drug use

Covariates
Age, ethnicity,
clinic site, selfrated health,
cardiac disease,
hypertension,
dyslipidemia,
education,
physical
activity, and
baseline TB FM
for TB LM as
an outcome
measure and TB
LM for
appendicular
LM as an
outcome
measure
Age, sex,
ethnicity, time,
height, weight,
physical
activity, and
nerve
conduction
velocity.

LM
measures
%TB LM
%Appendic
ular LM

Findings
Rapid decline in T2D group in contrast to NG group
Rapid decline in T2D group in contrast to NG group

TB LM
Leg LM

No difference between groups
No difference between groups

Age, clinic,
TB LM
Slight decline from baseline within the DSE group
ethnicity,
Trunk LM
Slight decline from baseline within the DSE group
HbA1c, time,
Leg LM
Slight decline from baseline within the DSE group
and baseline
body
composition
measure
Abrreviation: GMD, glucose metabolism disorder; NHANES, the National Health and Nutrition Examination Survey; KSOS, the
Korean Sarcopenic Obesity Study; Health ABC Study, the Health, Aging, and Body composition Study; NG, normoglycemic, T2D,
type 2 diabetic; DSE, Abrreviation: GMD, glucose metabolism disorder; NHANES, the National Health and Nutrition Examination
Survey; KSOS, the Korean Sarcopenic Obesity Study; Health ABC Study, the Health, Aging, and Body composition Study; NG,
normoglycemic, T2D, type 2 diabetic; DSE, diabetes support and education; ILI, intensive lifestyle intervention; OGTT, oral glucose
tolerance test; FBG, fasting blood glucose; HbA1c, hemoglobin A1C; BMI, body mass index; TB LM, total body lean mass; HDL,
high-density lipoprotein cholesterol; BCAA, branched-chain amino acid; TC, total cholesterol; TG, triglyceride; CRP, C-reactive
protein; CHD, coronary heart disease; PAD, peripheral arterial disease; and COPD, chronic obstructive pulmonary disease .
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All studies have failed to use large sample sizes except for three cross-sectional
[31,32,34] and longitudinal [38,41,42] studies as shown in Tables 1 and 2. This may
explain limited power to detect differences in primary outcomes among glycemic groups.
Another limitation is that the study populations included middle-aged and older subjects
[28-34,38-42] in which findings cannot be generalized to their younger counterparts. A
further limitation is related to how the data were analyzed. One cross-sectional study
adjusted for TB FM and LM when testing the relationship between glycemic status and
regional body composition [28]. Two of the longitudinal studies adjusted for baseline
body composition measures when examing the relation of glycemic status to changes in
TB composition and its distribution [39,40]. The remaining studies controlled for body
mass index (BMI) [27,29,31,33,38] or body weight [32,37,38,42] and HbA1c [39] or
fasting blood glucose (FBG) [29,33] that could lead to an over-adjustment due to its high
correlation with body composition and glycemic measures. Sample size, adjustment for a
various covariates, and diagnosis of dysglycemia may account for the inconsistent
findings among studies.
Dysglycemia and Bone
Osteoporosis, which is a skeletal condition characterized by lower skeletal
mineralization in response to accelerated bone loss or making excessively minimal bone
in the body, is a risk factor for fracture. The 2005-2010 National Health and Nutrition
Examination Survey reported that 10.2 million American adults aged ≥ 50 years suffered
from osteoporosis and the number is projected to increase to 17.2 million in 2030 [44].
The prevalence of osteoporosis among pre-diabetic and T2D men aged ≥ 50 years is
15.1% and 33.3%, respectively [45,46]. Numerous studies have reported that pre-diabetes
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and T2D are associated with an increased risk of osteoporotic fractures up to threefold
[47-49], despite a normal to high bone mineral density (BMD) in patients with abnormal
glucose metabolism. This suggests that other factors, such as hyperglycemia,
accumulation of advanced glycosylation end products (AGEs), insulin resistance, and
bone quality, play a crucial role in inducing the osteoporotic fractures.
Hyperglycemia increases the expression levels of sclerostin that is inversely
associated with areal BMD (aBMD) [50] and suppresses bone anabolic pathways through
inhibition RNKL induced osteoclastogenesis and reduction of RNKL gene expression
during bone remodeling [51]. Hyperglycemia also leads to diminished osteoblast activity
and inhibited osteoblast differentiation via reduction of beta-catenin, cyclin D1, and cmyc gene expressions [52]. AGEs decrease bone strength and impair bone cells [53].
Insulin resistance is negatively associated with biomarkers of bone turnover [54] and
bone strength [55,56]. Several studies have revealed decreased bone turnover in T2D
[57,58]. Low biomarkers of bone resorption and bone formation were observed in T2D
patients [59].
Few studies have assessed the association between bone mineral content (BMC)
or aBMD and pre-diabetes. Most studies have reported no differences in aBMD at
multiple skeletal sites between pre-diabetic and normoglycemic men [60-64].
Conversely, other studies revealed pre-diabetic patients had higher aBMD at the femoral
neck (FN), hip and spine than control patients (Table 1.3) [65,66]. The effect of T2D on
bone health have been widely studied. Previous studies evaluating bone health and T2D
observed inconsistent findings regarding aBMD differences among patients with T2D
and normoglycemia. Comparable, higher or lower FN, hip and spine aBMD were found
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in T2D individuals as compared to their normoglycemic counterparts as presented in
Table 3 [60-65,67-75]. To date, only two longitudinal studies have evaluated the
association of baseline glycemic status with changes in aBMD at different skeletal sites.
These studies found no differences in bone measures among men across various glycemic
groups [62,76] (Table 1.3). However, Hamilton et al. [76] reported spine aBMD
increased in T2D men from baseline.
There are several possible explanations for mixed findings regarding the
association of glycemic status with bone health. Selection of study participants was from
varied settings including community-dwelling populations, and clinics or hospitals where
patients managed their condition based on the treatment management from specialists or
physicians. Previous studies were limited by age, various methods of measuring bone
mass, diverse study designs, and a lack of adjustment for TB FM and TB LM that may
affect bone mass differently. Surprisingly, only two studies adjusted for TB FM and LM
to produce an estimate of the glycemic effect on aBMD, independent of body
composition [62,73]. Bone size and width are independent risk factors for hip fracture
[77-79]. Recently, two studies examined the association of glycemic status with bone
area at the FN, hip, and spine [65,74]. Despite conflicting results, pre-diabetes and T2D
were negatively associated with FN bone area [65]. There is still gap on the association
between glycemic status and bone area. The effect of glycemic status on changes in bone
mass is not clear in men. Data on the transition from normoglycemia to pre-diabetes and
T2D and reversion from pre-diabetes to normoglycemia are lacking. This dissertation
aims to determine the association of changes in glycemic status with changes in aBMD,
BMC, and bone area at multiple skeletal sites.
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Table 1.3. Baseline and changes in bone mass by glycemic status.
Participants
(Follow-up
Study name
time)
Case-control studies
Clinic
Italian adults
Study[67]
aged 60-75 years,
50 NG and 110
T2D
Cardiovascular 274 Finnish men
Diseases and
aged 57-68 years,
Risk factors in
240 NG and 34
Diabetes[68]
T2D

DCROH [69]

Fremantle
Diabetes Study
[70]

105 Japanese
men aged 7475years, 41 NG
and 64 T2D
216 Australian
men aged 57-76
years, 108 NG
and 108 T2D

VHA [71]

1,100 US men
aged 67-68 years,
550 NG and 550
T2D
Cross-sectional studies
Hertfordshire
432 British men
Cohort Study
aged 62-67 years,
[61]
349 NG and 83
pre-diabetes

Health ABC
Study [62]

Rotterdam
Study[63]

BLSA [64]

Diagnosis of
dysglycemia

Covariates

Bone
measures

Findings

HbA1c and use
of antidiabetic
agents

Matched by
age, sex and
BMI

FN BMC
Spine BMC

Lower in T2D group than in NG group
Lower in T2D group than in NG group

HbA1c

Age, BMI,
duration of
diabetes,
duration of
insulin therapy,
insulin dose,
calcium intake,
and use of loop
diuretics
Matched by
age, and BMI

FN aBMD

No difference between groups

FN aBMD
Spine aBMD

No difference between groups
No difference between groups

Age and BMI

FN aBMD
hip aBMD
Spine aBMD

No difference between groups
No difference between groups
No difference between groups

Matched by
age, BMI,
smoking, and
alcohol intake

FN aBMD
Spine aBMD

Lower in T2D group than in NG group
Greater in T2D group than in NG group

Age, BMI,
cigarette,
alcohol intake,
current social
class, physical
activity
NA

FN aBMD
Spine aBMD

No difference between groups
No difference between groups

FN aBMD
hip aBMD

No difference between groups
No difference between groups

FN aBMD
Spine aBMD

No difference between groups
No difference between groups

FN aBMD
hip aBMD
Spine aBMD

No difference between groups
No difference between groups
No difference between groups

FBG, HbA1c,
and use of
antidiabetic
agents
HbA1c, use of
antidiabetic
agents, and
diagnosed
between 40 and
60 years of age
FBG and HbA1c

OGTT

740 US White
and Black men
aged 71-77 years,
564 NG and 176
pre-diabetic
5,183 Dutch
adults aged 5983 years,3,888
NG and 1,295
pre-diabetic

OGTT

394 US men
aged 53-82 years,
285 NG and 109
pre-diabetic

OGTT

OGTT

Age, gender,
BMI, smoking,
lower limb
disability, use
of thiazides,
and use of loop
diuretics
Age, BMI, race,
smoking,
multivitamin
use, calcium
and vitamin D
supplementatio
n, serum
creatinine,
serum vitamin
D, serum
calcium, and
current and
prior
bisphosphonate
use
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Table 1.3. Baseline and changes in bone mass by glycemic status- continued.

Study name
ULSAM [65]

BEH [66]

Participants
(Follow-up
time)
384 Swedish
men aged 81-83
years. 234 NG
and 150 prediabetic
1,804 Iranian
adults aged 6376 years, 1,184
NG and 620 prediabetic

Diagnosis of
dysglycemia
FBG

FBG and HbA1c

Rancho
Bernardo [60]

180 US men
aged 64-82 years,
139 NG and 41
T2D

FBG, OGTT,
and T2D
diagnosed by
physician

SAFOS [72]

217 MexicanAmerican men
aged 62- years,
162 NG and 55
T2D

OGTT, selfreported, and use
of antidiabetic
agents

Hertfordshire
Cohort Study
[61]

402 British men
aged 62-67 years,
349 NG and 33
T2D

OGTT

Health ABC
Study [73]

1,456 US White
and Black men
aged 71-77 years,
1,133 NG and
323 T2D

FBG, selfreported, and use
of antidiabetic
agents

Health ABC
Study [62]

822 US White
and Black men
aged 71-77 years,
564 NG and 258
T2D
4,451 Dutch
adults aged 5983 years,3,888
NG and 563 T2D

FBG, OGTT,
self-reported,
and use of
antidiabetic
agents
OGTT and use
of antidiabetic
agents

Rotterdam
Study [63]

Covariates
Age, education,
height, BMI,
smoking status,
and physical
activity
Age, gender,
physical
activity, current
smoking, and
BMI
Age, BMI,
cigarette
smoking,
alcohol use,
regular
exercise, and
use of diuretic
Age, Age2,
BMI, smoking,
physical
activity,
calcium intake,
alcohol intake,
and use of
diuretics
Age, BMI,
cigarette,
alcohol intake,
current social
class, physical
activity
Study site,
current
smoking,
current
drinking,
performance
battery score,
previous
diagnosis of
osteoporosis,
use of
osteoporosis
medications,
TB fat, and TB
lean
NA

Age, gender,
BMI, smoking,
lower limb
disability, use
of thiazides,
and use of loop
diuretics

Bone
measures
hip aBMD
hip BA

FN aBMD
Spine aBMD

Findings
Greater in pre-diabetic group than in
NG group
Lower in pre-diabetic group than in NG
group
Greater in pre-diabetic group than in
NG group
Greater in pre-diabetic group than in
NG group

FN aBMD
Spine aBMD

No difference between groups
No difference between groups

Spine aBMD

No difference between groups

FN aBMD
Spine aBMD

No difference between groups
Greater in T2D group than in NG group

hip aBMD

Greater in T2D group than in NG group

FN aBMD
hip aBMD

Greater in T2D group than in NG group
Greater in T2D group than in NG group

FN aBMD
Spine aBMD

Greater in T2D group than in NG group
Greater in T2D group than in NG group
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Table 1.3. Baseline and changes in bone mass by glycemic status- continued.
Study name
BACH/Bone
Survey[74]

Participants
(Follow-up
time)
US men aged 4658 years, 995 NG
and 142 TD

Diagnosis of
dysglycemia
Self-reported
and use of
antidiabetic
agents

Bone
measures
FN aBMD
Spine aBMD

Findings
No difference between groups
No difference between groups

FN BMC
Spine BMC

No difference between groups
No difference between groups

FN BA
Spine BA

No difference between groups
No difference between groups

FN aBMD
hip aBMD
Spine aBMD

No difference between groups
No difference between groups
No difference between groups

hip aBMD
hip BA

Greater in T2D group than in NG group
Lower in T2D group than in NG group

FBG and use of
antidiabetic
agents

Age, BMI, race,
smoking,
multivitamin
use, calcium
and vitamin D
supplementatio
n, serum
creatinine,
serum vitamin
D, serum
calcium, and
current and
prior
bisphosphonate
use
Age, education,
height, BMI,
smoking status,
and physical
activity
Age, gender,
height, and
weight

FN aBMD

No difference between groups

OGTT

*See footnote

FN aBMD
hip aBMD

No difference between groups
No difference between groups

BLSA [64]

370 US men
aged 53-82 years,
285 NG and 85
T2D

OGTT

ULSAM [65]

302 Swedish
men aged 81-83
years. 234 NG
and 68 T2D

FBG, selfreported, and use
of antidiabetic
agents

Framingham
1,069 US adults
Offspring
aged 56-73 years,
Cohort Study
940 NG and 129
T2D
[75]
Longitudinal studies
Health ABC
740 US White
Study [62]
and Black men
aged 71-77 years,
564 NG and 176
pre-diabetic
(Over 4-year
follow-up)

Covariates
Age, race, BMI,
and physical
activity
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Table 1.3. Baseline and changes in bone mass by glycemic status- continued.
Participants
(Follow-up
Study name
time)
Longitudinal studies - continued
Health ABC
822 US White
Study [62]
and Black men
aged 71-77 years,
564 NG and 258
T2D
(Over 4-year
follow-up)
Fremantle
16 Australian
Diabetes Study T2D men aged
[76]
56-74 years (over
5-year follow-up)

Diagnosis of
dysglycemia
FBG, OGTT,
use of
antidiabetic
drug, and selfreported

Covariates
*See footnote

Bone
measures
FN aBMD
hip aBMD

Findings
No difference between groups
No difference between groups

HbA1c, use of
Age and BMI
FN aBMD
No change from baseline
antidiabetic
hip aBMD
No change from baseline
agents, and
Spine aBMD Increased from baseline
diagnosed
between 40 and
60 years of age
Abbreviation: T2D, type 2 diabetic; HbA1c, hemoglobin A1c, BMI, body mass index; FN, femoral neck; BMC, bone mineral content;
NG, normoglycemic; aBMD, areal bone mineral density; DCROH, Diabetes Clinic of Rakuwakai Otowa Hospital; FBG, fasting blood
glucose; VHA, Veterans Health Administration; OGTT, oral glucose tolerance test; BEH, Bushehr Elderly Health program; SAFOS,
Sant Antonio Family Osteoporosis Study; Health ABC Study, Health, Aging and Body Composition Study; NA, no adjustment for
covariates; BACH/Bone Survey, Baston Area Community Health/Bone Survey; BA, bone area; BLSA, Baltimore Longitudinal Study
of Aging; ULSAM, Uppsala Longitudinal Study of Adult Men.
*FN models adjusted for age, baseline weight, weight change during follow-up, TB lean mass, IL-6, use of oral steroid, and baseline
hip aBMD.
*Hip models adjusted for age, baseline weight, weight change during follow-up, TB lean mass, IL-6, use of vitamin D supplement,
and baseline FN aBMD.

Dysglycemia and Lipid Profile
Insulin resistance, central to the pathogenesis of pre-diabetes and T2D,
contributes to disturbances in lipid and lipoprotein metabolism. Dyslipidemia,
characterized by hypertriglyceridemia, an increased concentration of small, dense lowdensity lipoprotein cholesterol (LDL-C) and a decreased concentration of high-density
lipoprotein cholesterol (HDL-C) is common in pre-diabetic and T2D patients, resulting in
an increased risk of cardiovascular disease (CVD) [3,80]. Elevated fatty acids released
from the adipocyte into the circulation is induced by insulin resistance in pre-diabetes and
T2D. The flux of free fatty acids to the liver enhances synthesis and secretion of very
low-density lipoprotein (VLDL) leading to an increased concentration of triglyceride
(TG). The exchange between TG of VLDL and cholesterol esters of LDL and HDL is
regulated by cholesterol ester transfer protein. Hepatic lipase hydrolyzes TG in LDL and
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HDL particles resulting in smaller, denser LDL particles and a lower concentration of
HDL-C through enhanced HDL clearance from plasma [81-83].

According to the National Health and Nutrition Examination Survey, the
prevalence of dyslipidemia among pre-diabetic and T2D adults aged ≥ 20 years in the US
in 2011-2014 was 51.2% and 63.2%, respectively [84]. Since dyslipidemia in patients
with pre-diabetes is identical to those with T2D, lipid target goals for pre-diabetes should
be similar to T2D [3]. The primary target goal for LDL-C is <100 mg/dL in individuals
with pre-diabetes and T2D without coronary heart disease (CHD) and <70 mg/dL in
individuals with pre-diabetes or T2D and CHD. If TG is >200 mg/dL, the secondary
target goal for non-HDL-C is <130 mg/dL in pre-diabetic and T2D individuals. The third
target goal for HDL-C is >40 mg/dL in pre-diabetic and T2D individuals [85,86]. The
ADA criteria for lipid targets are <100 mg/dL for LDL-C, >40 mg/dL for HDL-C in men
and <150 mg/dL for TG [87].

The association of pre-diabetes with lipid and lipoprotein abnormalities has been
extensively investigated, but the diagnosis of pre-diabetes (impaired fasting glucose
(IFG) versus impaired glucose tolerance (IGT)) contributes to inconsistent findings. IFG
has consistently shown a positive association with TC, LDL-C, and TG, but no
association with HDL-C (Table 4) [88-90]. On the other hand, IGT has an opposite
association with lipid profile, including negative correlation with HDL-C, positive
correlation with TG, and no correlations with TC and LDL-C (Table 4) [88-92].

The site of insulin resistance in the pre-diabetic state can explain discrepancies
among cross-sectional studies. In the presence of IFG, VLDL is elevated in response to
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increased hepatic TG lipoprotein synthesis. This leads to increased production and
secretion of hepatic apo B-100 resulting in hypertriglyceridemia [93]. Hyperinsulinemia
promotes free fatty acid flux to the liver through suppression of adipocyte lipolysis with
increases in the hepatic secretion of VLDL resulting in hypertriglyceridemia. Also, a
decrease in lipoprotein lipase activity of adipose tissue contributes to reduced VLDL
breakdown and elevations in TG concentrations [93]. In the state of IGT, impaired fatty
acid uptake and oxidation in skeletal muscle lead to the accumulations of free fatty acids
and lipids that promote hepatic synthesis and secretion of TG-enriched VLDL particles
that are exchanged for TG-enriched LDL and HDL particles by cholesterol ester transfer
protein [94,95]. Hepatic TG lipase hydrolyzes TG-enriched LDL and HDL particles and
accelerates clearance of LDL and HDL particles resulting in an increase in small, dense
LDL particles and a decrease in concentration of HDL-C [95].

It has previously been observed that TC and LDL-C normally remain unaltered in
individuals with T2D compared to their normoglycemic counterparts [91,92,96,97].
However, atherogenic dyslipidemia, comprising of decreased HDL-C concentration and
increased TG concentration, is common in T2D patients as presented in Table 3 [88,9092,96,97]. Up to now, little attention has been paid to the effects of changes in glycemic
status on changes in lipids and lipoproteins. The San Antonio Heart Study examined the
relation between conversion from normoglycemia or pre-diabetes to T2D and baseline
lipid profile over 8-year follow-up. These investigators found no difference in the lipid
profiles between converters to T2D and non-converters as shown in Table3 [98,99].
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Only two clinical trials have attempted to investigate changes in glycemic status
in relation to changes in lipid profile [100,101]. The experimental data are rather
controversial, and there is no general agreement about reversion from pre-diabetes to
normoglycemia associated with improvement in lipid profile and conversion from
normoglycemia/pre-diabetes to T2D being associated with worsening lipid profile.
Regression from pre-diabetes to normoglycemia was correlated with an increase in HDLC and a reduction in TG, whereas progression from normoglycemia to pre-diabetes was
associated with an increase in LDL-C and a decrease in HDL-C. Conversion from prediabetes to T2D was associated with declines in LDL-C and HDL-C [100]. Nevertheless,
Nanditha et al. [101] reported no differences in changes in TC, HDL-C, and TG among
pre-diabetic men who reverted to normoglycemia and those who remained pre-diabetic,
while increases in TC and TG were observed in pre-diabetic men who progressed to T2D
compared to those who remained pre-diabetic throughout the study (Table 4) [101].
Much uncertainty still exists about the relation between regression to normoglycemia or
progression to pre-diabetes and T2D and changes in lipids and lipoproteins. This
dissertation seeks to determine whether the transition from pre-diabetes to
normoglycemia is associated with favorable lipid profile and transition from
normoglycemia or pre-diabetes to T2D is associated with worsening lipid profile.
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Table 1.4. Baseline and changes in lipid profile by glycemic status.
Participants
(Follow-up
Study name
time)
Case-control studies
Screening
725 Bulgarian
Program for
adults aged 41Risk of T2D
64 years, 477 NG
[88]
and 248 IFG

Diagnosis of
dysglycemia

Covariates

Lipid
measures

Findings

FBG

Matched by age
and BMI

TC
LDL-C
HDL-C
TG

Greater in IFG group than in NG group
Greater in IFG group than in NG group
Lower in IFG group than in NG group
Greater in IFG group than in NG group

Screening
674 Bulgarian
Program for
adults aged 41Risk of T2D
69 years, 477 NG
[88]
and 197 IGT
Screening
795 Bulgarian
Program for
adults aged 44Risk of T2D
69 years, 477 NG
[88]
and 318 T2D
Cross-sectional studies
Rancho
833 US men
Bernardo
aged 69-74 years,
Study [91]
593 NG and 240
IGT
Rancho
754 US men
Bernardo
aged 69-75 years,
Study [91]
593 NG and 161
T2D
Study Clinic
189 US White
[96]
and Hispanic
men aged 32-57
years, 148 NG
and 41 T2D
UKPDS [97]
2191 British men
aged 43-61 years,
52 NG and 2139
T2D
DECODE [89] 7141 European
men aged 35-74
years, 5403 NG
and 1738 IFG

OGTT

Matched by age
and BMI

FBG and
OGTT

Matched by age
and BMI

TC
LDL-C
HDL-C
TG
TC
LDL-C
HDL-C
TG

No difference between groups
No difference between groups
Lower in IGT group than in NG group
Greater in IGT group than in NG group
Greater in T2D group than in NG group
No difference between groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group

OGTT

FBG, OGTT,
and T2D
diagnosed by
a physician
OGTT

Age, BMI,
smoking,
alcohol intake,
and excerise
Age, BMI,
smoking,
alcohol intake,
and excerise
Age and BMI

TC
LDL-C
HDL-C
TG
TC
LDL-C
HDL-C
TG
LDL-C
HDL-C
TG

No difference between groups
No difference between groups
Lower in IGT group than in NG group
No difference between groups
No difference between groups
No difference between groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group
No difference between groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group

FBG

NA

FBG

No difference between groups
No difference between groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group
Greater in IFG group than in NG group
No difference between groups
Greater in IFG group than in NG group
Greater in IFG group than in NG group

DECODE [89]

6505 European
men aged 35-74
years, 5403 NG
and 1102 IGT

OGTT

TC
HDL-C
TG
TC/HDL

No difference between groups
Lower in IGT group than in NG group
Greater in IGT group than in NG group
Greater in IGT group than in NG group

Communitydwelling
adults: RomeTor and
Catanzaro
Areas [102]
METSIM [90]

544 Italian adults
aged 28-64 years,
416 NG and 128
pre-diabetes

HbA1c

Age, study
center, waist
circumference,
smoking,
systolic blood
pressure, and
fasting insulin
Age, study
center, waist
circumference,
smoking,
systolic blood
pressure, and
fasting insulin
Age and gender

TC
LDL-C
HDL-C
TG
TC
HDL-C
TG
TC/HDL

TC
HDL-C
TG

No difference between groups
Lower in pre-diabetic group than in NG
group
Greater in pre-diabetic group than in NG
group

7379 Finish men
aged 50-64 years,
3034 NG and
4345 IFG

FBG

TC
LDL-C
HDL-C
TG

Greater in IFG group than in NG group
Greater in IFG group than in NG group
No difference between groups
Greater in IFG group than in NG group

Age, family
history of
diabetes,
physical activity
during leisure
time, BMI,
waist
circumference,
and use of
statins
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Table 1.4. Baseline and changes in lipid profile by glycemic status- continued.

Study name
METSIM [90]

Participants
(Follow-up
time)
3346 Finish men
aged 50-67 years,
3034 NG and
312 IGT

Diagnosis of
dysglycemia
OGTT

Covariates
Age, family
history of
diabetes,
physical activity
during leisure
time, BMI,
waist
circumference,
and use of
statins
Age, family
history of
diabetes,
physical activity
during leisure
time, BMI,
waist
circumference,
and use of
statins
Age, gender,
educational
level, and
family history
of diabetes

Lipid
measures
TC
LDL-C
HDL-C
TG

Findings
No difference between groups
No difference between groups
Lower in IGT group than in NG group
Greater in IGT group than in NG group

TC
LDL-C
HDL-C
TG

Greater in T2D group than in NG group
No difference between groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group

TC
LDL-C
HDL-C
TG

No difference between groups
No difference between groups
Lower in pre-diabetic group than in NG
group
Greater in pre-diabetic group than in NG
group

METSIM [90]

Finish men aged
50-66 years,
3034 NG and
650 T2D

FBG and
OGTT

PREDAPS
[103]

1452 Spanish
adults aged 3074 years, 838 NG
and 614 prediabetes

FBG and
HbA1c

CATAMERI
[104]

894 Italian
adults aged 4053 years, 602 NG
and 292 prediabetes

HbA1c

Age, gender,
and BMI

TC
HDL-C
TG

No difference between groups
Lower in pre-diabetic group than in NG
group
Greater in pre-diabetic group than in NG
group

CATAMERIS
[92]

953 Italian adults
aged 30-64 years,
721 NG and 232
IGT

OGTT

Age, gender,
and waist
circumference

TC
LDL-C
HDL-C
TG
TG/HDL

No difference between groups
No difference between groups
Lower in IGT group than in NG group
Greater in IGT group than in NG group
Greater in IGT group than in NG group

CATAMERIS
[92]

779 Italian adults
aged 30-64 years,
721 NG and 58
T2D

OGTT

Age, gender,
and waist
circumference

TC
LDL-C
HDL-C
TG
TG/HDL

No difference between groups
No difference between groups
Lower in T2D group than in NG group
Greater in T2D group than in NG group
Greater in T2D group than in NG group

CATAMERI
[105]

644 Italian adults
aged 27-66 years,
425 NG and 239
pre-diabetes

HbA1c

Age, gender,
and BMI

TC
LDL-C
HDL-C
TG

No difference between groups
No difference between groups
Lower in pre-diabetic group than in NG
group
Greater in pre-diabetic group than in NG
group

FBG, OGTT,
and use of
anti-diabetic
agents

Age, BMI, and
fasting insulin
concentration

TC
LDL-C
HDL-C
TG

No difference between groups
No difference between groups
No difference between groups
No difference between groups

Longitudinal studies
Sant Antonio
614 Mexican
Heart Study
American adults
[98]
aged 25-64 years,
571 NG to NG
and 43 NG/IGT
to T2D (8-year
follow-up)
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Table 1.4. Baseline and changes in lipid profile by glycemic status- continued.

Study name
San Antonio
Heart Study
[99]

Lifestyle
Intervention
Program [101]

Participants
(Follow-up
time)
1734 Mexican
and NonHispanic White
American adults
aged 25-64 years,
1539 NG to NG
and 195 NG/IGT
to T2D (7-year
follow-up)
343 Asian Indian
men aged 41-52
years, 192 IG to
NG and 151 IGT
to IGT (2-year
follow-up)

Diagnosis of
dysglycemia
OGTT and
use of antidiabetic
agents

Covariates
Age, gender,
ethnicity,
fasting glucose,
waist
circumference,
and insulin
resistance

Lipid
measures
LDL-C
HDL-C
TG

Findings
No difference between groups
No difference between groups
No difference between groups

OGTT

Age, treatment
TC
No difference between groups
group, family
HDL-C
No difference between groups
history of
TG
No difference between groups
diabetes,
baseline 2-hour
plasma glucose,
baseline and
change in BMI,
HOMA-IR,
insulinogenic
index, dietary
energy intake,
and physical
activity
TC
Increased in IGT to T2D group compared
Lifestyle
343 Asian Indian
OGTT
Age, treatment
to IGT to IGT group
Intervention
men aged 41-52
group, family
history of
HDL-C
No difference between groups
Program [101]
years, 151 IGT to
diabetes,
TG
Increased in IGT to T2D group compared
IGT and 79 IGT
to IGT to IGT group
to T2D (2-year
baseline 2-hour
follow-up)
plasma glucose,
baseline and
change in BMI,
HOMA-IR,
insulinogenic
index, dietary
energy intake,
and physical
activity
Abbreviation: T2D, type 2 diabetes; NG, normoglycemic, IFG, impaired fasting glucose; FBG, fasting blood glucose; BMI, body
mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG,
triglyceride; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; UKPDS, United Kingdom Prospective Diabetes
Study; NA, no adjustment for covariates; DECODE, Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe;
TC/HDL TC to HDL-C ratio, HbA1c, hemoglobin A1c; METSIM, Metabolic Syndrome In Men; PREDAPS, Primary Health Care on
the Evolution of Patients with Prediabetes; CATAMERI, CATAnzaro Metabolic Risk factor; CATAMERIS, CATAnzaro Metabolic
Risk factor Study; TG/HDL, TG to HDL-C ratio; NG to NG, normoglycemic remained normoglycemic; NG/IGT to T2D,
normoglycemic or pre-diabetic converted to type 2 diabetes; IG to NG, pre-diabetic reverted to normoglycemia; IGT to IGT, prediabetic remained pre-diabetic; and IGT to T2D, pre-diabetic converted to type 2 diabetes.

Statement of the Problem
There have been increases in the number of cases of pre-diabetes and T2D among
US adults due to the aging population and the increase in the prevalence of pre-diabetes
and T2D among US adults may be due to an increase in the rate of obesity. The growing
economic burden of pre-diabetes and T2D is attributed to the increasing prevalence as
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well as the use and cost of health care services [106,107]. The primary key to prevention
of prediabetes and T2D is lifestyle modifications. There is accumulating epidemiological
evidence indicating that unfavorable body composition [108-112] and lipid profile [113117] are risk factors for pre-diabetes and T2D, but little is known about the effect of
change in glycemic status on subsequent changes in lipid profile. Until now, only two
clinical trials have shown that reversion from pre-diabetes to normoglycemia had
favorable changes in lipid biomarkers [100,101]. To date, no observational longitudinal
study has determined the association of change in glycemic status (progression from
normoglycemia or pre-diabetes to T2D or regression from pre-diabetes to
normoglycemia) with changes in body composition and lipid profiles. Only three
longitudinal studies have evaluated the impact of pre-diabetes and T2D on changes in
BMC and aBMD at different bone sites, but the findings are unclear [62,67,118]. To fill
these critical gaps and move the research field, the present study was to investigate the
association of change in glycemic status with changes in body composition, measures of
bone health (bone area, BMC, and aBMD at multiple sites), and lipid profiles in male
adults across a wide age range (20 to 66 years).
Overall Aim
The overall objective of this dissertation was to investigate the effects of baseline
and changes in glycemic status on baseline and changes in body composition, bone, and
lipid profile. This dissertation used data from the ongoing longitudinal South Dakota
Rural Bone Health Study (SDRBHS) of a cohort of 1,271 participants aged 20 to 66 years
who were enrolled between 2001 and 2004. The analysis was limited to men due to the
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higher prevalence of pre-diabetes and T2D in men than women, and data from the
baseline and year three follow-up visits were used.
Specific Aims
Three specific aims were addressed:
Aim 1. To examine the associations between baseline and changes in glycemic status with
baseline and changes over three years in TB, trunk, and appendicular FM and LM.
The following hypotheses were tested:
1. Men with prediabetes or T2D at baseline would have higher TB and trunk fat
measurements but lower appendicular fat than normoglycemic men.
2. Men who were normoglycemic at baseline and developed either prediabetes or
T2D would have increases in TB and trunk FM, and decreases in TB and
appendicular LM over the three-year study compared with men who remained
normoglycemic.
3. Among men with prediabetes at baseline, the changes in TB and trunk FM and
LM would differ over the three-year study depending on whether they remained
prediabetic or developed T2D versus reverting to a normoglycemic state. Those
who develop T2D would gain TB FM and lose LM, while those reverting to
normoglycemia would lose FM and maintain or gain LM.
4. Men with T2D at baseline would have decreases in TB and trunk LM over the
three-year study compared to normoglycemic men.
Aim 2. To determine both cross-sectional and longitudinal relationships between bone
measures (BMC and aBMD) and glycemic status in men after taking into account
differences in body composition.
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The following hypotheses were tested:
1. Men with pre-diabetes or T2D at baseline would have higher BMC and aBMD
compared to normoglycemic individuals, but these differences would not remain
significant when controlling for differences in body composition.
2. Normoglycemic or pre-diabetic men who developed T2D would have similar
changes in BMC and aBMD as men who remained normoglycemic after adjusting
for differences in body composition.
3. Among men with pre-diabetes, the change in BMC and aBMD would differ
depending on whether they developed T2D or reverted to the normoglycemic
state. Men developing T2D would have decreases in BMC and aBMD compared
to men who remain pre-diabetic after adjusting for body composition, while those
reverting to a normoglycemic state would maintain or increase their BMC and
aBMD.

Aim 3. To determine the effects of cross-sectional and longitudinal changes in glycemic
status on baseline and changes in lipid biomarkers and ratios.

The following hypotheses were tested:

1. Pre-diabetic and T2D men would have greater TC, LDL-C, TG, cardiac risk ratio
(CRR), and atherogenic index of plasma (AIP) and lower HDL concentrations
than normoglycemic men at baseline.
2. TC, LDL-C, TG, RCC, and AIP concentrations would increase, and HDL
concentrations would decrease, in normoglycemic men who developed prediabetes or T2D.
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3. TC, LDL-C, TG, CRR, and AIP concentrations would decrease, and HDL
concentrations would increase, in pre-diabetic men who reverted to
normoglycemia compared to prediabetic men who remained pre-diabetic.
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Abstract
Objective: This study sought to evaluate the associations between changes in glycemic
status and changes in total body (TB), trunk, and appendicular fat (FM), and lean mass
(LM) in men.
Methods: A population-based study of men aged 20–66 years at baseline were included
in cross-sectional (n = 430) and three-year longitudinal (n = 411) analyses. Prediabetes
was defined as fasting glucose 100–125 mg/dL. Type 2 diabetes (T2D) was determined
by: self-reported diabetes, current anti-diabetic drug use (insulin/oral hypoglycemic
agents), fasting glucose (≥126 mg/dL), or non-fasting glucose (≥200 mg/dL). Body
composition was evaluated by dual-energy X-ray absorptiometry.
Results: Longitudinal analyses showed that changes in TB FM and LM, and appendicular
LM differed among glycemic groups. Normoglycemic men who converted to prediabetes
lost more TB and appendicular LM than men who remained normoglycemic (all, p <
0.05). Normoglycemic or prediabetic men who developed T2D had a greater loss of TB
and appendicular LM than men who remained normoglycemic (both, p < 0.05). T2D men
had greater gains in TB FM and greater losses in TB and appendicular LM than men who
remained normoglycemic (all, p < 0.05).
Conclusion: Dysglycemia is associated with adverse changes in TB and appendicular
LM.
Keywords: prediabetes; type 2 diabetes; total body fat; total body lean; appendicular fat;
appendicular lean; body composition; cohort study
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Introduction
Prediabetes and type 2 diabetes (T2D) are major public health issues in the United
States. The national prevalence of prediabetes and T2D among adults aged ≥20 years has
increased over time, with the prevalence of prediabetes rising from 26% in 1988–1994 [1]
to 37% in 2009–2012 [2]. Recent estimates from the Centers for Disease Control and
Prevention indicate that 15–30% of prediabetic cases progress from impaired fasting
glucose or impaired glucose tolerance to T2D within five years. There are currently 25.8
million adults in the United States with prediabetes that will develop T2D by 2020, which
will double the number of individuals affected by T2D [3]. The prevalence of T2D rose
from 7% in 2005 to 12% in 2011 [4], and is projected to increase 165% by 2050 [5].
Case-control and cross-sectional studies have reported inconsistent associations of
total body (TB), trunk, and appendicular fat mass (FM) and lean mass (LM) with
prediabetes and T2D diabetes in middle-aged and older adults, including a positive
association [6], an inverse association [7–10], and no association [6,8,9]. Prospective
studies aimed at investigating the relationship between baseline glycemic status and
subsequent changes in TB and regional distribution of FM and LM are sparse and
inconclusive. Some studies reported differences in body composition measurements among
glycemic groups [11–14], but others did not find differences [15,16]. The possible
explanation for inconsistent findings includes different durations of follow-up period,
sample size, and other covariates that were not adjusted for when investigating the
association between various measures of body composition and glycemic status. We found
no epidemiological studies that investigated the association between glycemic status (men
with prediabetes who revert to normoglycemia, or men who are normoglycemic or
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prediabetic at baseline and convert to T2D) and changes in the TB and regional distribution
of FM and LM.
The objective of the present analysis was to examine the associations between baseline
and changes in glycemic status with baseline and changes over three years in TB, trunk,
and appendicular FM and LM. The following a priori hypotheses were tested: (1) men with
prediabetes or T2D at baseline would have higher TB and trunk fat measurements but lower
appendicular fat than normoglycemic men; (2) men who were normoglycemic at baseline
and developed either prediabetes or T2D would have increases in TB and trunk FM, and
decreases in TB and appendicular LM over the three-year study compared with men who
remained normoglycemic; (3) among men with prediabetes at baseline, the changes in TB
and trunk FM and LM would differ over the three-year study depending on whether they
remained prediabetic or developed T2D versus reverting to a normoglycemic state. Those
who develop T2D would gain TB FM and lose LM, while those reverting to
normoglycemia would lose FM and maintain or gain LM; and (4) men with T2D at baseline
would have decreases in TB and trunk LM over the three-year study compared to
normoglycemic men.
Methods
Study Population
The South Dakota Rural Bone Health Study is a population-based longitudinal study
designed to investigate the impact of lifestyle factors on bone and body composition. The
design and rationale of the study have been described elsewhere [17]. Briefly, adults aged
20 to 66 years, from eight counties in eastern South Dakota, were eligible for enrollment.
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A total of 1271 participants were recruited between 2001–2004 (baseline), and followed
for an average of 3.0 years (range of 2.8 to 3.8 years), and the current analysis was limited
to men (n = 544). Among those participants, 410 men farmed at least 75% of their lives
(rural) and 134 men never lived on an active farm (non-rural). The rural population was
divided into Hutterites and non-Hutterites. A Hutterite was defined as a participant of
Hutterite descent who resided on a Hutterite colony. Hutterites are an Anabaptist religious
group who believe in isolated communal living and self-sufficiency through an
agriculturally advanced lifestyle. Non-Hutterites were randomly selected from the eightcounty region as described elsewhere [17].
Men with chronic use (> six months) of immunosuppressants, anticonvulsants, or
steroids or a diagnosis of type 1 diabetes mellitus at baseline were not eligible for
inclusion in the original cohort. For baseline analyses, we excluded men with missing
glucose measures at either baseline (n = 12) or follow-up (n = 34), baseline body
composition measurements (n = 23), or men who withdrew from the study (n = 45)
(Figure 2.1). For follow-up analyses, we further excluded men who did not have body
composition measurements at follow-up (n = 19). These exclusions led to 430 men in the
baseline analyses and 411 in the follow-up analyses. The study was approved by the
South Dakota State University Institutional Review Board (IRB#1406004), and informed
consent was obtained from all of the participants.
Assessment of Covariates
Questionnaires were administered at study enrollment and at three years to obtain
information on demographic and lifestyle characteristics as well as quarterly physical
activity and dietary intake recalls. Information on smoking status and specific details
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regarding the use of prescription drugs was not collected at baseline; however, an 18-month
survey was used to obtain this information. Participants were asked to provide information
on types of smoking, such as cigarettes, cigars, and pipes, and were classified as smokers
or non-smokers. The presence or absence of hypertension at 18 months was based on selfreported information on the use of antihypertensive medication.
Anthropometric Measures
Body height and weight were measured in lightweight clothes without shoes using a
calibrated stadiometer and scale. Standing height was measured to the nearest 0.5 cm in
duplicate with a stadiometer (Seca, Chino, CA, USA). A third measurement was taken if
the discrepancy between the duplicate height measurements was more than 0.5 cm. Weight
was measured to the nearest 0.1 kg with a digital scale (Seca Model 770, Chino, CA, USA).
Physical Activity Assessment
The Paffenbarger Physical Activity Questionnaire (PPAQ) was used to measure the
average amount of time spent in sedentary behaviors and different intensity levels of
physical activity during the past week [18]. Participants were asked to recall how many
hours on their usual weekday and weekend day they spent sleeping, sitting, and engaging
in moderate or vigorous intensity activity. Since the time spent in sleeping, sitting, and
participating in moderate plus vigorous activity was measured, the remaining time was
considered light activity. The PPAQ was administered quarterly over the first three years
of the study. To properly report participants’ physical activity, trained personnel
administered the PPAQ by interview. The average time spent in sitting and moderate-plusvigorous activity, as well as the average sleeping time, was calculated. The validity and
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reliability of the PPAQ have been established to measure physical activity intensities in
men [19] and rural populations [20].
Dietary Assessment
Dietary intake was assessed using 24-h dietary recalls that were conducted at similar
times as the activity recall. Trained interviewers administered 24-h dietary recalls, and
dietary recall data were analyzed using Nutritionist Pro software (version 2.3.1, 2004, First
DataBank, Inc., San Bruno, CA, USA) to estimate macronutrient and micronutrient intakes.
For foods not available in the Nutritionist Pro software, the nutrient composition of the
foods was obtained from recipes and entered into the diet analysis software. Activity levels
and nutrient intakes at baseline were the averages of the baseline, three-month and sixmonth recalls, and measures at the 36-month visit were the averages of the 30-month, 33month, and 36-month recalls.
Ascertainment of Glycemic Status
According to American Diabetes Association classifications, individuals with a fasting
blood glucose of 100 mg/dL to 125 mg/dL were classified as having prediabetes [21]. T2D
was determined by one of the following criteria: self-reported T2D, current use of an antidiabetic drug (insulin or oral hypoglycemic agents), or a fasting blood glucose
concentration ≥126 mg/dL or a non-fasting blood glucose concentration ≥200 mg/dL [21].
The same criteria for the diagnosis of prediabetes and T2D were applied at both the baseline
and three-year visits. Attempts were made to obtain fasting blood samples at each visit,
and measurements were made in the field from a sample of venous whole blood (with
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added ethylenediaminetetraacetic acid) using an Accu-Check Advantage glucometer
(Roche Diagnostics, Indianapolis, IN, USA).
Body Composition Measurements
Body composition was assessed using dual-energy x-ray absorptiometry (DXA)
(Discovery, Software Version 12.01, Hologic, Waltham, MA, USA). A TB scan was
completed with boundaries for the various anatomical regions set according to
manufacturer’s specifications. The step phantom scan for body composition calibration
was completed weekly as suggested by the manufacturer. Prior to DXA measurements, the
Hologic spine phantom was scanned for quality control. All of the scans were analyzed by
the same technician who was certified by the International Society of Clinical
Densitometry. Scan results were deleted for obese participants with an equivalent epoxy
thickness greater than 12 inches, as determined by the Hologic software, per manufacturer
recommendations (n = 16 men: n = seven Hutterite, n = four rural, n = five non-rural).
DXA-derived measurements of TB, trunk and appendicular FM and LM were expressed in
kilograms. Our coefficients of variation for TB FM and LM assessed in 15 adults (one
male) using triplicate scans with repositioning between each scan are <1.5%.
Statistical Analysis
All of the continuous variables were tested for normality before performing the
analyses. Analysis of variance adjusting for multiple comparisons for continuous variables
and a Fisher’s exact test for categorical variables were used to determine statistical
significance in baseline characteristics among the glycemic categories. The annual absolute
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change in each body composition measure was calculated as the follow-up value minus
baseline value divided by length of follow-up in years.
Multiple regression models were used to estimate marginal means ± standard error of
the mean (sem) for baseline body composition parameters and changes in outcome
measures by different categories of glycemic status. Differences in marginal means among
glycemic groups were evaluated using post hoc contrast tests based on the hypotheses. A
priori determined covariates (age at baseline, height, population group, percent time in
moderate-plus-vigorous activity, and total daily caloric intake) were included in all of the
models, since they were found to be associated with at least one body composition measure.
The multiple regression models that were used for baseline analyses included these
covariates, and the FM model included the LM of the same compartment (TB, trunk, or
appendicular), and the LM model included covariates plus the FM of the same
compartment. Multiple regression models for the longitudinal analyses were adjusted for
the same covariates, as well as changes in percent time in moderate-plus-vigorous activity
and total daily caloric intake between baseline and three-year follow-up, baseline measure
of the specific body compartment (TB, trunk, or appendicular), and baseline and annual
changes in the FM or LM of same compartment. Due to issues with multicollinearity and
the problem of body composition measures being components of both body mass index
(BMI) and weight, neither BMI nor weight was included as covariates. The assumptions
of linearity, normality, and homoscedasticity were evaluated visually to ensure no violation
of assumptions. All of the analyses were performed using JMP software (version 13, SAS
Institute, Cary, NC, USA), and the statistical significance level was set at p < 0.05 (twotailed).
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Results
Subject Characteristics
At the baseline visit, 358 (83.2%) of the men were normoglycemic, 51 (11.9%) were
prediabetic based on fasting glucose concentrations, and 21 (4.9%) had T2D (14 selfreported a medical diagnosis, six based on fasting glucose, and one based on non-fasting
glucose). Of the 345 men who were normoglycemic at baseline and for whom glucose and
body composition measurements were available at three years, 272 (78.9%) remained
normoglycemic, 65 (18.8%) progressed to prediabetes, and eight (2.3%) progressed to T2D
(five based on fasting glucose, one based on non-fasting glucose, one self-reported a
medical diagnosis, and one taking anti-diabetic medication). Among the 48 prediabetic
men, 19 (39.6%) remained prediabetic, 25 (52.1%) reverted to normoglycemic, and four
(8.3%) progressed to T2D based on fasting glucose concentrations. Of the 18 T2D men
who were diabetic throughout the study, four (22.2%) self-reported a medical diagnosis,
11 (61.1%) were taking anti-diabetic medication, and three (16.7%) had T2D based on
fasting glucose concentrations.
Participant characteristics by glycemic categories at baseline and follow-up are
summarized in tables 2.1 and 2.2. The mean age (+ sem) was 42.7 ± 0.6 years (range: 20
to 66 years), and men with T2D at baseline were older than those who were
normoglycemic. The study population was 37.4% Hutterite, 37.2% rural non-Hutterite, and
25.4% non-rural. Hutterites and married men had a higher prevalence of prediabetes and
T2D than non-Hutterites and single men. Men with prediabetes weighed more than
normoglycemic men. A higher percentage of prediabetic and T2D men were taking
antihypertensive medication than normoglycemic men, and carbohydrate intake was
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greater in normoglycemic men than in prediabetic and T2D men. At follow-up, men with
T2D had lower caloric and carbohydrate intake than men who remained normoglycemic
throughout the study or men who were normoglycemic and developed prediabetes (Table
2.2). Prediabetic men who remained prediabetic at three years increased their carbohydrate
intake, and men who remained normoglycemic throughout the study increased their weight,
time spent in moderate-plus-vigorous activity, and average daily fat intake. The overall
mean changes over the three-year study in percent time in moderate-plus-vigorous activity
and average dietary intake of calories, carbohydrates, fat, and protein were not significant
(mean changes were 0.6 ± 0.4%, 10 ± 28 kcal, 1.0 ± 3.8 g, 3.0 ± 1.6 g, and 0.0 ± 1.5 g,
respectively), and changes in caloric and macronutrient intakes did not differ by glycemic
categories (data not shown).
Cross-Sectional Assessment of Baseline Body Composition in Men with Prediabetes or
Type 2 Diabetes
There were no differences in TB, trunk, or appendicular FM or LM among the three
glycemic groups at baseline when covariates were included in the analyses (Table 2.3).
Prediabetic men weighed more than normoglycemic men.
Association between Development of Prediabetes and Type 2 Diabetes and Changes in
Body Composition
Changes in body composition for the six glycemic groups are shown in Figures 2.2
and 2.3. There were differences among men who developed prediabetes or T2D and men
who remained normoglycemic regarding the annual change in TB and appendicular LM.
Among men who were normoglycemic at baseline, those who progressed to prediabetic
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lost more TB and appendicular LM than those who remained normoglycemic (Figure 2.3).
Normoglycemic or prediabetic men who developed T2D also had greater losses in TB and
appendicular LM than men who remained normoglycemic (Figure 2.3).
Changes in Body Composition among Prediabetic Men Depending on Reversion to
Normoglycemia
There were no differences in the FM or LM between prediabetic men who remained
prediabetic and those that reverted to normoglycemia (Figures 2.2 and 2.3). In general,
prediabetic men who reverted to normoglycemia had negative changes in FM, whereas
men who remained prediabetic had positive changes.
Changes in Body Composition among Type 2 Diabetic Men
Men who were T2D at baseline had greater gains in TB FM (Figure 2.2) and greater
losses in TB and appendicular LM (Figure 2.3) than men who remained normoglycemic
over the three-year follow-up.
Discussion
This is the first prospective population-based cohort study investigating the association
of baseline glycemic status and changes in glycemic status over time with changes in TB,
trunk, and appendicular FM and LM. Consequently, the findings of prior observational
longitudinal studies cannot be compared to our findings. The findings of the current study
indicate that there were no baseline differences among glycemic groups in TB, trunk, or
appendicular FM and LM. Normoglycemic men who developed prediabetes or T2D had
greater losses in TB and appendicular LM than men who remained normoglycemic. Men
who had T2D throughout the study period had greater gains in TB FM, and greater losses
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in TB and appendicular LM, than men who were normoglycemic throughout the study. No
differences were observed in changes in weight or body composition measures among
prediabetic men who reverted to normoglycemia compared to those who remained
prediabetic.
Contrary to our first hypothesis, we did not find differences in TB and regional FM
and LM at baseline among the glycemic groups. The present study differs from other
studies [6–8,10,22,23] due to the adjustment for covariates and inclusion of other body
composition compartments (e.g., when determining whether TB FM was associated with
glycemic status, TB LM was included in the statistical model). The inclusion of these
covariates resulted in the relationships becoming non-significant.
Consistent with our hypothesis, normoglycemic men who developed prediabetes or
T2D had greater losses in TB and appendicular LM than men who remained
normoglycemic, but we found no association with changes in FM. A positive association
between glucose concentrations and intermuscular adipose tissue has been reported [24],
and it has been suggested that hyperglycemia stimulates the differentiation of mesenchymal
stem cells derived from adipose and muscle tissues into adipocytes by activating the protein
kinase C β pathway [25]. Other studies also have reported an association between
hyperglycemia and reduced TB and appendicular LM in men [10]. The underlying
mechanisms of the decline in LM may include elevated circulating concentrations of
inflammatory markers and oxidative stress. Biomarkers of inflammation, tumor necrosis
factor alpha, and C-reactive protein stimulate the loss of skeletal muscle through the
activation of nuclear factor kappa B [26] and the inhibition of protein synthesis [27].
Oxidative stress contributes to a catabolic and anabolic imbalance in skeletal muscle,
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mitochondrial damage, and muscle atrophy and apoptosis [28]. These findings indicate that
elevated inflammation markers in the presence of oxidative stress in prediabetic and T2D
men can induce the loss of TB and appendicular LM. The present findings from the study
support these reports.
The association of changes in prediabetes status over time with changes in body
composition by compartments have not been previously investigated. A few prospective
studies have examined changes in TB and appendicular FM and LM in prediabetic
individuals compared to normoglycemic controls. Our findings are similar to other studies
reporting no difference in longitudinal changes in TB and lower extremity LM between
individuals with and without prediabetes [14,16,29]. On the contrary, others have reported
a loss in TB FM and appendicular LM that was greater in prediabetics compared to their
normoglycemic counterparts [14,29].
In addition to greater gains in TB FM among men with T2D than among
normoglycemic men, we found a significant loss in TB and appendicular LM among men
who either had T2D at baseline or developed T2D during the study compared to men who
remained normoglycemic. By contrast, Park et al. [15] reported no differences in
longitudinal changes in TB and appendicular FM and LM between older adults with
normoglycemia and those diagnosed T2D. Our findings are consistent with longitudinal
studies that have found T2D men gained TB FM and lost TB and appendicular LM [12–
14]. The mechanism for fat gain and muscle loss may stem from insulin resistance in T2D.
An excessive influx of free fatty acids into the systemic circulation resulting from the
adipose tissue contributes to insulin resistance by increasing fat accumulation in the liver
leading to decreased insulin clearance, and increasing fat accumulation in skeletal muscle
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by impairing glucose transport, decreasing muscle protein synthesis, and inducing muscle
protein breakdown, leading to a reduced muscle surface area and insulin signaling [30, 31].
The strengths of our study include the first prospective population-based study of the
association between changes in glycemic status and changes in TB and regional body
composition measured by DXA, our low dropout rate, and our statistical adjustment for the
same body composition compartments. Our study has several limitations. The present
study included predominantly white men, and our findings may not be generalizable to
women or other races. The majority of the men were farmers who may have different
activity patterns and dietary intake than non-farmers, which may influence the relationship
between dysglycemia and body composition. However, a study conducted on a
representative sample of the United States (U.S.) population reported a similar association
between dysglycemia and reduced lean mass [10]. Another limitation is the sample size of
some of the glycemic categories. We did not observe differences between those men who
were prediabetic at baseline and remained prediabetic, or reverted to normoglycemia as we
hypothesized. It is likely that our sample size (n = 19 and 25, respectively) was too small.
Based on the observed means and standard deviations in changes in TB FM, we estimate
that 72 men per group would be needed (α = 0.05, β = 0.20). Despite the small sample size
in some categories, we did observe other differences that we hypothesized, including
differences in changes in TB and appendicular LM between normoglycemic men who
developed prediabetes or T2D and those who remained normoglycemic throughout the
study. We relied on participants’ recall of diagnosis of T2D, antidiabetic medication usage,
dietary intake, and physical activity. A self-reported diagnosis of T2D or the use of
antidiabetic medication can lead to misclassification due to recall or reporting errors.
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Dietary and physical activity recalls may result in overestimation or underestimation.
However, dietary intake and physical activity assessments were performed quarterly to
consider seasonality. The 24-h diet recall [32] and PPAQ [19] are valid measures of dietary
intake and physical activity in adults. Although this was a longitudinal study, given the
period of time between measurements (three years), it is not possible to determine whether
changes in glycemic status preceded changes in body composition or vice versa. Future
studies should be over longer periods of time with more frequent measures of glycemic
status and body composition in order to determine which factor comes first: dysglycemia
or body composition changes. Only one fasting or non-fasting blood glucose measurement
per visit was obtained for defining prediabetes and T2D. Although the American Diabetes
Association recommends different criteria for screening for prediabetes and T2D using
glycated hemoglobin, fasting blood glucose, and two-hour plasma glucose after an oral
glucose tolerance test [21], numerous studies have reported that using two-hour plasma
glucose test detects more cases of prediabetes and diabetes than using glycated hemoglobin
or a fasting blood glucose test [33–38]; thus, we might have missed men with prediabetes
and T2D using only one fasting blood glucose measurement, which would have made it
more difficult to identify group differences in changes in body composition.
Conclusion
In conclusion, (1) there were no differences among glycemic groups in baseline TB
and regional distribution of FM and LM; (2) men who were normoglycemic at baseline
and developed prediabetes or T2D had greater losses in TB and appendicular LM than men
who remained normoglycemic; (3) there were no differences in changes in body weight or
composition among men who were prediabetic at baseline and remained prediabetic
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compared to those who reverted back to normoglycemia; and (4) men who had T2D at
baseline had greater gains in TB FM and greater losses in TB and appendicular LM than
normoglycemic men. These findings add to a growing body of literature on the associations
between changes in glycemic status and body composition.
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Table 2.1. Baseline characteristics of the 430 men from the South Dakota Rural
Bone Health Study cohort. NH: non-Hutterite.

Participants (n)

Normogly
cemic

Pre-diabetic

T2D

358

51

21

41.6 ± 0.6 a

45.8 ± 1.7

53.0 ± 2.6 a

p-Value 1

Demographics
Age (years)
Population Group (%)

<0.001
0.001

Hutterite (n = 161)

73.3

18.0

8.7

NH Rural (n = 160)

89.3

8.8

1.9

NH Non-rural (n = 109)

89.0

7.3

3.7

81.3

92.2

95.2

0.06

Height (cm)

177.9 ± 0.4

177.9 ± 0.9

174.3 ± 1.5

0.06

Weight (kg)

91.1 ± 0.8 a

98.5 ± 2.1 a

95.9 ± 3.3

0.003

Smokers (%)

33.2

24.0

38.1

0.43

BP Meds (%)

8.7

23.5

47.6

<0.001

21.8 ± 0.5

23.1 ± 1.4

19.3 ± 2.1

0.32

Total energy (kcal)

2373 ± 33

2218 ± 87

2060 ± 135

0.03 3

Carbohydrate (g)

265 ± 5 ab

224 ± 12 b

202 ± 19 a

<0.001

Fat (g)

97 ± 2

98 ± 4

90 ± 7

0.55

Protein (g)

105 ± 2

102 ± 4

102 ± 7

0.80

Ever Married (%)
Anthropometrics

Lifestyle Variables

% Time in MVPA 2
Daily Macronutrient Intake 2

Values are means ± sem or n (percentages). 1 Significance based on ANOVA for continuous variables and
Fisher’s exact test for categorical variables; means with similar superscripts are different using a post hoc
Tukey test. 2 Physical activity levels and nutrient intakes at baseline were the average of the baseline, 3-and
6-month recalls. 3No means differed by post-hoc Tukey test for multiple comparisons. Abbreviations: T2D,
type 2 diabetic; NH, non-Hutterite; BP Meds, hypertensive medications; MVPA, moderate-plus-vigorous
physical activity.
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Table 2.2. Anthropometrics, activity levels, and diet intake of the 411 men from the South Dakota Rural Bone Health
Study cohort, according to glycemic categories after three years of follow-up.
Baseline:

Normoglycemic

Pre-diabetic

Normoglyce
mic or Prediabetic

T2D

Pre-diabetic

Normoglyce
mic

Pre-diabetic

T2D

T2D

272

65

25

19

12

18

Baseline Age (years)

41.0 ± 0.7 ab

42.6 ± 1.5 c

43.9 ± 2.6

47.1 ± 2.3

51.9 ± 2.3 b

53.0 ± 2.2 ac

<0.001

Baseline Height (cm)

177.9 ± 0.4

177.0 ± 0.8

179.4 ± 1.0

176.9 ± 2.0

175.3 ± 1.7

175.1 ± 1.7

0.17

Baseline

90.3 ± 0.9 ‡

92.5 ± 2.0

96.1 ± 3.3

98.8 ± 3.9

100.4 ± 4.1

96.0 ± 3.1

0.01 3

Follow-Up

91.5 ± 0.9

93.3 ± 2.0

95.2 ± 3.4

100.1 ± 4.3

98.3 ± 4.0

96.0 ± 3.3

0.08

Baseline

21.0 ± 0.6 ‡

23.7 ± 1.2

22.6 ± 1.7

24.4 ± 2.3

26.2 ± 3.0

19.8 ± 2.1

0.11

Follow-Up

22.5 ± 0.6

22.1 ± 1.1

19.9 ± 1.6

21.9 ± 2.1

24.5 ± 2.5

22.8 ± 2.4

0.77

Baseline

2344 ± 38

2435 ± 75

2284 ± 130

2140 ± 106

2248 ± 183

2067 ± 108

0.18

Follow-Up

2382 ± 38 a

2386 ± 81 b

2268 ± 102

2211 ± 95

2176 ± 189

1898 ± 132 ab

0.02

263 ± 5 a

268 ± 11

239 ± 17

208 ± 14 ‡

233 ± 21

204 ± 15 a

0.003

Follow-Up:
Participants (n)

Normoglycemic

p-Value
1

Weight (kg)

% Time MVPA 2

Daily Intake 2
Total Energy (kcal)

Carbohydrate (g)
Baseline

65

Follow-Up

265 ± 5 a

267 ± 13 b

248 ± 16

232 ± 14

208 ± 19

186 ± 16 ab

0.001

95 ± 2

102 ± 4

101 ± 7

94 ± 6

94 ± 10

91 ± 8

0.57

100 ± 3

95 ± 5

98 ± 6

99 ± 11

90 ± 8

0.75

Fat (g)
Baseline
Follow-Up

101 ± 2

‡

Protein (g)
Baseline

103 ± 2

107 ± 4

105 ± 7

96 ± 5

101 ± 11

101 ± 6

0.79

Follow-Up

104 ± 2

106 ± 3

105 ± 5

98 ± 5

107 ± 11

93 ± 8

0.50

Values are unadjusted means ± sem or n (percentages). ‡ Significant change from baseline to follow-up based on paired t-test. 1 Significance
among glycemic categories based on ANOVA for continuous variables and Fisher’s exact test for categorical variables; means with similar
superscripts are different using a post hoc Tukey test. 2 Physical activity (PA) levels and nutrient intakes at baseline were the averages of the
baseline, three-month, and six-month recalls, and at follow-up were the averages of 30-month, 33-month, and 36-month recalls. 3 No means
differed by post hoc Tukey test for multiple comparisons. Abbreviations: T2D, type 2 diabetic; MVPA, moderate-plus-vigorous physical
activity.
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Table 2.3. Total body and regional body composition in the 430 men from the
South Dakota Rural Bone Health Study cohort, according to glycemic status at
baseline.
p-Value 1

Normoglycemic

Pre-diabetic

T2D

358

51

21

Unadjusted Model

91.1 ± 0.8 a

98.5 ± 2.1 a

95.9 ± 3.3

0.003

Basic Model 2

91.0 ± 0.8 a

97.0 ± 3.2 a

95.9 ± 3.2

0.01

22.1 ± 0.5 ab

26.4 ± 1.2 b

26.7 ± 1.9 a

0.001

22.6 ± 0.3

24.0 ± 0.9

23.3 ± 1.5

0.38

11.4 ± 0.3 ab

14.2 ± 0.8 b

15.1 ± 1.2 a

<0.001

11.8 ± 0.2

12.6 ± 0.5

11.8 ± 0.9

0.38

Unadjusted Model

9.6 ± 0.2 a

11.1 ± 0.5 a

10.4 ± 0.8

0.01

Full Model 3

9.7 ± 0.2

10.3 ± 0.4

10.1 ± 0.7

0.66

Unadjusted Model

67.0 ± 0.4

69.9 ± 1.2

66.8 ± 1.8

0.07

Full Model 4

67.1 ± 0.3

67.9 ± 0.8

67.9 ± 1.2

0.56

Unadjusted Model

32.7 ± 0.2 a

34.5 ± 0.6 a

34.1 ± 0.9

0.01

Full Model 4

32.7 ± 0.1

33.1 ± 0.4

33.8 ± 0.6

0.24

Unadjusted Model

30.5 ± 0.2

31.6 ± 0.6 a

28.9 ± 0.9 a

0.04

Full Model 4

30.5 ± 0.2

31.0 ± 0.4

30.3 ± 0.7

0.44

Participants (n)
Body Weight (kg)

Fat Mass (kg)
Total Body
Unadjusted Model
Full Model 3
Trunk
Unadjusted Model
Full Model 3
Appendicular

Lean Mass (kg)
Total Body

Trunk

Appendicular

Data are means and marginal means ± sem. 1 p-values are from multiple regression models. Means
with similar superscripts are different using a post hoc contrast test. 2 Basic model adjusted for
age, height, population group, percent time in moderate-plus-vigorous activity, and average daily
calories. 3 Fat mass models included covariates in basic model plus lean mass of same
compartment (total body, trunk, or appendicular). 4 Lean mass models included covariates in basic
model plus fat mass of same compartment. Abbreviations: T2D, type 2 diabetic.
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Figure 2.1. Flowchart of participants. Abbreviations: DXA, dual-energy X-ray
absorptiometry; T2D, type 2 diabetic. Individuals who were unable to be
categorized into glycemic groups were excluded.
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Figure 2.2. Adjusted marginal means of annual change from baseline in total body
(p = 0.02), trunk (p = 0.06), and appendicular (p = 0.06) fat mass according to
categories of glycemic status during the three-year follow-up. Model included
baseline age, height, population group, percent time in moderate-plus-vigorous
activity, average caloric intake, baseline measures of fat and lean mass in the
specific body compartment (total body, trunk, or appendicular), changes in
percent time in moderate-plus-vigorous activity and average caloric intake, and
annual change in lean mass of the same compartment. Means with similar
superscripts are different using post hoc contrast tests based on hypotheses.
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Figure 2.3. Adjusted marginal means of annual change from baseline in total body
(p = 0.004), trunk (p = 0.24), and appendicular (p < 0.001) lean mass according to
categories of glycemic status during the three-year follow-up. Model included
baseline age, height, population group, percent time in moderate-plus-vigorous
activity, average caloric intake, baseline measures of fat and lean mass in the
specific body compartment (total body, trunk, or appendicular), changes in
percent time in moderate-plus-vigorous activity and average caloric intake, and
annual change in the fat mass of the same compartment. Means with similar
superscripts are different using post hoc contrast tests based on hypotheses.
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Abstract
Background: The effect of various categories of glycemic status on bone mass and
density remains unknown. The aim of the current study was to determine the effect of
cross-sectional and longitudinal changes in glycemic status on bone mineral content
(BMC) and areal bone mineral density (aBMD) in men, aged 20-66 y, from the South
Dakota Rural Bone Health study.
Methods: Prospective study of 430 men (age: 42.7 ± 0.6 [SE]) with dual-energy x-ray
absorptiometry-derived indices of body composition and regional bone measures
obtained at baseline and three-year. Pre-diabetes was defined by fasting plasma glucose
100 to 125 mg/dL and type 2 diabetes (T2D) was determined by: self-reported T2D,
current use of anti-diabetic drug (insulin/oral hypoglycemic agents), or a fasting or nonfasting serum glucose concentration (≥126 and ≥200 mg/dL, respectively) at baseline and
follow-up. Multivariate analysis was used to estimate marginal means of baseline and
annualized percent change in bone outcomes among different categories of glycemic
status controlling for age, age2, height, population group, and total body fat and lean
mass.
Results: At baseline, femoral neck (FN) BMC and hip and FN aBMD were greater in
pre-diabetic and T2D men than normoglycemic men, but differences did not remain
significant after controlling for body composition. Relationship between hip aBMD and
lean mass was attenuated in pre-diabetic men vs. normoglycemic and T2D men (groupby-lean interaction, p = 0.004); similar results were observed with hip BMC and spine
aBMD. FN aBMD loss was greater in T2D men and men who were normoglycemic/prediabetic at baseline and developed T2D compared to normoglycemic men who developed
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pre-diabetes (all, p ≤ 0.05). Normoglycemic/pre-diabetic men who progressed to T2D
had greater loss in FN aBMD than men who were pre-diabetic and regressed to
normoglycemia (Figure 2).
Conclusion: Glycemic status has deleterious effects on bone and may modify the
relationships between bone and lean mass.
Keywords: pre-diabetes; type 2 diabetes; areal bone mineral density; bone mineral
content, aging
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Introduction

Osteoporosis, pre-diabetes, and type 2 diabetes (T2D) are major public health issues
in the United States [1,2]. The 2005-2010 National Health and Nutrition Examination
Survey reported that the prevalence of osteoporosis in men aged ≥50 years was 4.3%
(about 2 million men). Osteoporosis increases the risk of skeletal fractures, and the
estimated economic burden of osteoporotic fractures in adult men in the United States
aged ≥50 years was $4.1 billion in 2005 and is projected to increase by 27% in 2025 [1].
Pre-diabetes and diabetes also affect a large percent of U.S. adults aged 20 years or older
(37.2% and 10.4%, respectively), with approximately 86 million adults with pre-diabetes
and 30.4 million adults with diabetes in 2012. The estimated national total cost of prediabetes and diabetes in 2012 was $44 billion and $277 billion, respectively [2]. Fracture
risk has been reported to be elevated in individuals with T2D [3,4].

Numerous cross-sectional and case-control studies have evaluated the association
between pre-diabetes or T2D and bone health with inconsistent findings. Studies among
men with pre-diabetes or T2D find high [5-7], low [8-10], or similar BMC or aBMD at
multiple skeletal sites compared to men without diabetes [5,11-14]. A limited number of
longitudinal studies examining bone changes have been conducted in men with various
categories of glucose tolerance at baseline. Three prospective observational studies found
similar longitudinal changes in femoral neck (FN) BMC [8] and FN and hip aBMD
[15,16] among pre-diabetic, T2D, and normoglycemic men, whereas an increased spine
aBMD was observed in men with T2D [16]. The authors proposed that the observed
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increase in spine aBMD might be attributed to interference of aortic calcification on spine
aBMD measurements and degenerative spinal changes related to aging [16].

Bone measures are associated with body mass and the majority of observational
studies adjust for either body mass index (BMI) or body weight [5,7-9]. However, these
studies fail to consider the effect of body composition on bone mineral status. Total lean
mass is correlated with both insulin levels [17] and bone measures in normoglycemic and
T2D men [6,18-20]. Total lean mass directly affects bone mass through both gravitational
and muscle loads [21] and indirectly mediates the effect of insulin on bone health [17].
There is some controversy, however, on the influence of fat mass on bone [6,20,22].
Cross-sectional studies find a negative association between fat mass and FN aBMD [22],
but a positive correlation with hip aBMD in T2D men [6] and normoglycemic men
[19,20]. Increased fat mass also is associated with hyperinsulinemia that stimulates
secretion of peptides (insulin, preptin, and amylin), which in turn, may increase bone
mass by inhibiting osteoclastogenesis and enhancing osteoblastogenesis [23]. However,
elevation of pro-inflammatory cytokines is observed in pre-diabetic and T2D individuals
[24,25] and is associated with increased bone resorption [26]. Since body composition
may differ between men with and without pre-diabetes or T2D, it is important to control
for lean mass and fat mass individually when investigating whether or not there is an
association between bone health and glycemic status.
No studies have evaluated changes in BMC and aBMD in men who develop prediabetes, revert from pre-diabetic to the normoglycemic state, or convert from prediabetes to T2D. To the best of our knowledge, this is the first study to report the effect of
changes in glycemic status on longitudinal changes in BMC and aBMD.
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The objectives of this study were to determine both cross-sectional and longitudinal
relationships between bone measures (BMC and aBMD) and glycemic status in men and
the role of differences in body composition on these relationships. The South Dakota
Rural Bone Health (SDRBH) study is a population-based cohort study designed to
identify lifestyle risk factors affecting bone and body composition. Data from this
population-based longitudinal study were used to test the following hypotheses: (1)
individuals with pre-diabetes or T2D at baseline would have higher BMC and aBMD
compared to normoglycemic individuals, but these differences would not remain
significant when controlling for differences in body composition, (2) normoglycemic or
pre-diabetic men who developed T2D would have similar changes in BMC and aBMD as
men who remained normoglycemic after adjusting for differences in body composition,
and (3) among men with pre-diabetes, the change in BMC and aBMD would differ
depending on whether they developed T2D or reverted to normoglycemic state. Men
developing T2D would have decreases in BMC and aBMD compared to men who remain
pre-diabetic after adjusting for body composition, while those reverting to a
normoglycemic state would maintain or increase their BMC and aBMD.
Methods
Study population
From 2000 to 2004, 1,271 participants were recruited from eight counties in eastern
South Dakota as previously described [27]. Of these participants, 544 were men aged 20
to 66 years. Among those men, 410 men farmed at least 75% of their lives (rural), and
134 men never lived on an active farm (non-rural). The rural population was divided into
Hutterites and non-Hutterites. A Hutterite was a participant of Hutterite descent who
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resided on a Hutterite colony. Hutterites are an Anabaptist religious group who believes
in isolated communal living and self-sufficiency through an agriculturally advanced
lifestyle. Non-Hutterites were randomly recruited from the eight-county region as
described elsewhere [27].
Due to possible effects on bone, individuals with chronic use (>six months) of
immunosuppressants, anticonvulsants, or steroids or a diagnosis of type 1 diabetes
mellitus at baseline were excluded. For the current analyses, we excluded individuals
with missing information for blood glucose or bone measurements at either the baseline
or follow-up visit as well as individuals who withdrew from the study (Figure. 1). The
study was approved by the South Dakota State University Institutional Review Board,
and informed consent was obtained.
Body composition and bone measurements
Body composition of the total body and bone measurements of the left hip and spine
were measured at baseline and 36 months using dual-energy x-ray absorptiometry (DXA)
while wearing light clothing without shoes (Discovery Software Version 12.01, Hologic
INC., Bedford, MA). All scans were analyzed by one ISCD-certified technician. Scan
results were deleted for obese participants with an equivalent epoxy thickness greater
than 12 inches as determined by the Hologic software and per manufacturer
recommendations (16 men: 7 Hutterite, 4 rural, 5 non-rural). Quality control of the
scanner was assessed using the Hologic spine phantom. Quantification procedures
outlined by Orwoll et al. [28] were used to monitor and adjust results for longitudinal
fluctuations in scanner performance. Our coefficients of variation assessed in 15 adults (1
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male) using triplicate scans with repositioning between each scan were <1.5% for total
body lean and fat mass and <2% for hip and spine BMC and BA [29].
Anthropometric measurements
Body height and weight were measured in lightweight clothes without shoes using
calibrated stadiometer and scale. Standing height was measured in duplicate to the
nearest 0.5 cm in using a Seca stadiometer (Chino, CA). A third measurement was taken
if the discrepancy between the duplicate height measurements was more than 0.5 cm.
Weight was measured to the nearest 0.1 kg with a Seca digital scale (Model 770, Chino,
CA). BMI was calculated as weight (kg) divided by height (m2).
Ascertainment of pre-diabetes and type 2 diabetes
According to the American Diabetes Association, individuals with fasting plasma
glucose of 100 mg/dL to 125 mg/dL are classified as having pre-diabetes [30]. T2D was
determined by one of the following criteria: self-reported T2D, current use of an antidiabetic drug (insulin or oral hypoglycemic agents), or a fasting plasma glucose
concentration ≥126 mg/dL or a non-fasting plasma glucose concentration ≥200 mg/dL
[30]. The same criteria for the diagnosis of pre-diabetes and T2D were applied at both the
baseline and three-year visits. Glucose measurements were made in the field from a
sample of venous whole blood (EDAT) using an Accu-Check Advantage glucometer
(Roche Diagnostics, Indianapolis, IN). Based on these criteria, 51 men were classified as
pre-diabetic at baseline and 48 of them had follow-up data. Of these 48, 19 remained prediabetic, 25 reverted to normoglycemic, and 4 converted to T2D at three-year visit. Of
the 21 men classified as T2D at baseline, 14 self-reported a diagnosis of T2D and 7 were
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classified as T2D based on their blood sugar results. Of these 21, 18 were included in the
follow-up analysis with 4 self-reporting a diagnosis of T2D, 11 reported taking antidiabetic prescribed drugs, and 3 were classified as T2D based on their blood sugar
results.
Statistical analysis
Differences in baseline characteristics among different categories of glucose
intolerance were tested using one-way analysis of variance with Tukey HSD post hoc
comparison of means for continuous variables and chi-square test for categorical
variables. Glucose intolerance was entered in linear regression as an ordinal variable with
normoglycemic, pre-diabetic and T2D coded as 0, 1 and 2 to test for a linear trend and
was also considered a categorical variable when estimating marginal means for
annualized percent changes in outcome measures. Differences in marginal means among
glucose intolerance groups were evaluated using pairwise contrasts. Three regression
models were developed for each bone outcome. Model 1 did not include any covariates
and was based on a simple analysis of variance. Model 2 included age, age2 (to account
for the non-linear effect of age on bone outcomes), height, and population group as
covariates. Model 3 included covariates listed in Model 2 along with total body fat and
lean mass to determine whether there were differences in bone measures associated with
glycemic status independent of body composition. For models investigating annualized
percent change in bone measures, baseline bone and body composition measures, and
annual percent changes in total body fat and lean mass were added to the Model 3.
Glycemic status might moderate the relationship between baseline fat or lean mass on
baseline bone parameters and we tested the glycemic group-by-fat mass and glycemic
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group-by-lean mass interactions. All analyses were performed using JMP software
(version 13, SAS Institute, Cary, NC). Data are presented as means ± standard error (SE)
for quantitative variables and percentages for categorical variables, and the statistical
significance level was set at p ≤ 0.05.
Results
Baseline characteristics
Of the 544 men enrolled in the SDRBH study, 35 were missing glucose or body
composition measurements at baseline and another 79 either withdrew prior to 36 months
(n=45 [8.3% dropout rate]) or were missing blood glucose measurements at 36 months
(n=34) (Figure 2.1). Of the 430 men who could be categorized into groups of different
glycemic status at baseline, 19 did not have total body DXA measurements at 36 months
resulting in 411 men for whom there were both baseline and follow-up results. Among
the men participating in this study, 83.2% were normoglycemic, 11.9% were pre-diabetic
and 4.9% had T2D at baseline. Of the 358 men who were normoglycemic at baseline, 345
were included in the follow-up analyses. Of the 345, 272 (78.8%) maintained a constant
normoglycemic state, 65 (18.8%) developed pre-diabetes, and 8 (2.3%) progressed to
T2D. Among the 48 men who were pre-diabetic at baseline and included in the follow-up
analyses, 19 (39.6%) remained pre-diabetic, 25 (52.1%) reverted to normoglycemia, and
4 (8.3%) developed T2D.
At baseline, normoglycemic men were younger than men with T2D, had lower
weight than pre-diabetic men, and had lower BMI and fat mass than both pre-diabetic and
T2D men (Table 3.1). Although aBMD Z-scores tended to be higher in men with T2D,
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post hoc Tukey tests for multiple comparisons did not show any group differences.
Hutterite men were more likely to have pre-diabetes or T2D than rural and non-rural men
(Table 3.1).
There were significant baseline differences in age, weight, BMI, and fat mass among
the six groups at follow-up analyses (Table 3.2). Men who were normoglycemic at
baseline and remained normoglycemic were younger at baseline than T2D men or men
who were normoglycemic or pre-diabetic at baseline and converted to T2D. Men with
T2D throughout the study were older than men who progressed from normoglycemia to
pre-diabetes. Men who were normoglycemic throughout the study weighed less, had
lower BMI, and less fat mass then both men who were pre-diabetic throughout the study
and men who were either normoglycemic or pre-diabetic at baseline and progressed to
T2D. Additionally, men who were normoglycemic throughout the study had lower fat
mass than men who had T2D throughout the study.
Cross-sectional analysis
Bone indices at baseline are summarized in Table 3.3. Although the main effect of
glycemic status on FN BMC and FN and hip aBMD was significant after adjusting for
age, age2, height, and population group, there were no statistical differences among
groups after adjusting for fat and lean mass.
Longitudinal analysis
The only significant difference among categories of glycemic status was the annual
percent change in FN aBMD, which was only significant after adjusting for covariates in
Models 2 and 3 (Figure 3.2, Supplementary Table 3.1). The loss of FN aBMD was
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greater in T2D men and men who were normoglycemic or pre-diabetic at baseline and
developed T2D compared to normoglycemic men who developed pre-diabetes.
Normoglycemic or pre-diabetic men who progressed to T2D had greater loss in FN
aBMD than men who were pre-diabetic and regressed to normoglycemia (Figure 3.2).
Differences in unadjusted mean percent change in spine bone area among glycemic
groups did not remain significant after controlling for covariates (Supplementary Table
3.1).
Moderating effects of fat and lean mass
The moderating effect of glycemic status on the baseline relationships between bone
outcomes and fat or lean mass were investigated using the glycemic group-by-fat mass
and group-by-lean mass interactions. Glycemic status at baseline modified the
relationship between hip aBMD and lean mass (group-by lean interaction, p = 0.004)
with an expected positive correlation between hip aBMD and lean mass in the
normoglycemic and T2D men, but a weaker relationship among pre-diabetic men (Figure
3.3). Similar relationships were observed for hip BMC (group-by lean interaction, p =
0.04) and spine aBMD (group-by-lean interaction, p = 0.03) (data not shown).
Discussion
We examined the influence of glycemic status at baseline and follow-up on bone
health in a population-based study of men. We found, consistent with our first hypothesis,
that there were significant differences in baseline FN BMC and hip and FN aBMD by
glycemic status when controlling for age, age2, height, and populations group, but these
differences did not remain significant after adjusting for fat and lean mass. We also found
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that men who were normoglycemic or pre-diabetic at baseline and progressed to T2D had
the greatest loss in FN aBMD followed by men who were diabetic throughout the study.
Additionally, we showed that glycemic status at baseline modified the relationship
between bone measures and lean mass.
The impact of pre-diabetes and T2D on FN, hip, and spine BMC and aBMD in men
remains controversial. Our study provides further support for similar BMC and aBMD at
multiple sites among men with and without pre-diabetes and T2D as previously described
in cross-sectional studies [7,11-13], which contrasts to other findings [5,10]. We
observed greater FN BMC and FN and hip aBMD among pre-diabetic and T2D men
compared to normoglycemic men at baseline after controlling for age, height and
population. However, when adjusting for fat mass and lean mass, these differences were
no longer significant which is contrary to the findings of Strotmeyer et al. [6] who
showed higher hip aBMD among older adults with T2D, independent of fat and lean
mass. Strotmeyer et al. [6] observed an inverse relationship between hip aBMD and T2D
duration, indicating that hip aBMD varied among T2D individuals with a long duration of
disease. This may partially explain the inconsistency with our study, although we did not
have information on duration of T2D among our participants. Our findings indicate that
given two groups of men of identical body composition, one with T2D and one without
T2D, the group with T2D would have similar bone mass to the group without T2D. It
also suggests that the tendency toward higher aBMD Z-scores among T2D men is a result
of differences in body composition and not T2D per se.
Previous studies suggest that higher circulating concentrations of insulin, IGF-I, and
sclerostin may explain the greater BMC and aBMD among pre-diabetics and diabetics
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[31-34]. Insulin is anabolic to osteoblasts, which may contribute to differences in bone
mass [31]. Insulin resistance or hyperinsulinemia, which is higher in individuals with prediabetes and newly diagnosed T2D, induces the synthesis of IGF-I and inhibits the
synthesis of IGF binding protein I in the liver, hereby increasing serum IGF-I
concentrations into the circulatory system [32]. IGF-I stimulates bone formation by
regulating osteoblast differentiation and proliferation and inducing synthesis of collagen
to increase bone matrix production and bone mass [33,34]. Cutrim et al. [35] report that
FN aBMD is positively associated with circulating IGF-I concentrations in T2D
individuals. Sclerostin, expressed by osteocytes, is higher in pre-diabetic and T2D
individuals due to its association with fasting glucose and glycated hemoglobin [36,37].
Sclerostin concentrations are positively associated with FN, hip and spine aBMD. Low
bone turnover can potentially account for the correlation between sclerostin and aBMD
[37].
There is no epidemiological evidence for the role of glycemic status as a moderator
of the impact of body composition on bone measures, and total body fat and lean mass
may affect bone in individuals with pre-diabetes and T2D differently than in individuals
with normoglycemia. As far as we know, this is the first study to report a moderating
effect of different categories of glycemic status on the relationship between lean mass
and bone health. Strong correlations between bone measures and lean mass have been
reported previously [20], believed to be in response to the loads muscle contractions
place on bone [21]. We observed a positive relationship between baseline total hip aBMD
and lean mass, but this relationship was attenuated among men with pre-diabetes. The
reason for this attenuation among men with pre-diabetes but not T2D is not known. There
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is a positive association between hip aBMD and muscle strength, suggesting that muscle
force or contraction exerts loads on bone [38], and perhaps a reduced muscle strength in
pre-diabetes contributes to the lower hip aBMD among pre-diabetics compared to
normoglycemic men that were observed with greater lean mass.
Previous prospective observational studies have primarily examined the influence of
pre-diabetes and T2D on FN bone loss. In contrast to earlier findings [15,16], T2D men
had greater FN aBMD loss than men who became pre-diabetic. We believe that we are
the first to report a greater loss in FN aBMD in men who were normoglycemic or prediabetic at baseline and developed T2D compared to those who were pre-diabetic and
reverted to normoglycemia. The association between FN aBMD loss and glycemic status
was attenuated, but remained statistically significant, after adjustment for initial aBMD
and annual percent changes in total fat and lean mass. Acute hyperglycemia is
accompanied by elevation of pro-inflammatory cytokines in pre-diabetes and T2D [3941] that induce bone loss through stimulation of osteoclast differentiation and impaired
bone formation [42]. Long-term exposure to hyperglycemia in T2D men may explain
why men who were T2D throughout the study or developed T2D had greater loss of FN
aBMD than men who developed pre-diabetes.
Strengths of our population-based study include a high retention rate, a wide age
range, evaluation of progression to pre-diabetes and regression to normoglycemia effects
on bone health for the first time, and not only an examination of changes in bone
measures across various categories of glycemic status, but an examination of interactions
between glycemic status and body composition on bone mass and density. Our study has
several limitations. First, the study population is predominately Caucasians, therefore;
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our findings cannot be generalized to other racial groups. Second, we are unable to adjust
for other covariates in our analysis that may affect aBMD, including insulin and proinflammatory cytokine concentrations, the duration of pre-diabetes and T2D, or oral
pharmacological therapy for T2D. Third, diagnosis of T2D and use of antidiabetic agents
were based on self-report; thus, there was potential misclassification. Finally, only one
fasting or non-fasting glucose measurement was obtained at baseline and was used as a
screening tool for identifying men with pre-diabetes and T2D. Several studies have
reported that a 2-h plasma glucose test identifies more pre-diabetic and diabetic cases
than a blood glucose test; therefore, we might have misclassified men with pre-diabetes
or T2D as normoglycemic.
Conclusion
In this population-based cohort study of men aged 20 to 66 years, we found no effect
of baseline glycemic status on bone measures after adjusting for differences total body fat
mass and lean mass. However, the relationship between aBMD and lean mass varied by
glycemic group. Change in glycemic status at follow-up was associated with FN aBMD,
with the greatest bone loss among men who developed T2D during the study or had T2D
throughout the study. These findings may elucidate an increased fracture risk in T2D and
further studies are warranted to confirm our findings.
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Table 3.1. Baseline characteristics by glycemic status.
Participants (n)
Age (y)

p-Value 1

Normoglycemia

Pre-diabetes

T2D

358

51

21

45.8 ± 1.7

53.0 ± 2.6a

41.6 ± 0.6

a

Population group (%)

<0.001
<0.001

Hutterite (n=161)

73.3

18.0

8.7

NH Rural (n=160)

89.3

8.8

1.9

NH Non-rural (n=109)

89.0

7.3

3.7

Height (cm)

177.9 ± 0.4

177.9 ± 0.9

174.3 ± 1.5

0.06

Weight (kg)

91.1 ± 0.8

a

a

95.9 ± 3.3

0.003

BMI (kg/m2)

28.8 ± 0.2ab

31.1 ± 0.6b

31.5 ± 1.0a

<0.001

67.0 ± 0.4

69.9 ± 1.2

66.8 ± 1.8

0.07

b

a

<0.001

Lean mass (kg)
Fat mass (kg)

22.1 ± 0.5

ab

98.5 ± 2.1

26.4 ± 1.2

26.7 ± 1.9

aBMD Z-scores
Femoral neck

0.34 ± 0.05

0.63 ± 0.12

0.71 ± 0.19

0.022

Total hip

0.45 ± 0.05

0.75 ± 0.12

0.84 ± 0.19

0.012

Lumbar spine

0.17 ± 0.07

0.58 ± 0.19

0.76 ± 0.29

0.022

Values are means ± SE or frequency (percentages). Means with similar superscripts are different using a
post hoc Tukey test for multiple comparisons. 1 P-values are based on ANOVA for continuous variables
and chi-square test for categorical variables. 2 No difference between glucose status groups using a post hoc
Tukey test for multiple comparisons. Abbreviations: T2D = type 2 diabetes; NH = non-Hutterite; BMI =
body mass index; aBMD = areal bone mineral density.
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Table 3.2. Baseline characteristics of participants by glycemic status at baseline and follow-up.
Baseline:

Normoglycemia
Normoglycemia

Pre-diabetes

Normoglycemia

Pre-diabetes
Normoglycemia

or Pre-diabetes

Pre-diabetes

T2D

T2D
T2D

p-Value

Follow-Up:
Participants (n)

1

272

65

25

19

12

18

41.0 ± 0.7ab

42.6 ± 1.5c

43.9 ± 2.4

47.1 ± 2.8

51.9 ± 3.5b

53.0 ± 2.8ac

Baseline variables
Age (y)

<0.001
<0.0012

Population group (%)
Hutterite (n=154)

50.7

22.1

8.4

7.1

4.6

7.1

NH Rural (n=151)

80.1

8.6

6.0

2.0

1.3

2.0

NH Non-rural (n=106)

68.9

17.0

2.8

4.7

2.8

3.8

Height (cm)

177.9 ± 0.4

177.0 ± 0.8

179.4 ± 1.3

176.9 ± 1.5

175.3 ± 1.9

175.1 ± 1.5

0.17

Weight (kg)

90.3 ± 0.9ab

92.5 ± 1.9

96.1 ± 3.0

98.8 ± 3.4b

100.4 ± 4.3a

96.0 ± 3.5

0.0134

BMI (kg/m2)

28.5 ± 0.3ab

29.5 ± 0.6

29.9 ± 0.9

31.6 ± 1.0b

32.7± 1.3a

31.4 ± 1.1

<0.001

66.6 ± 0.5

67.5 ± 1.0

69.2 ± 1.6

70.0 ± 1.9

70.3 ± 2.4

67.4 ± 1.9

0.22

21.6 ± 0.5abc

23.0 ± 1.1

24.7 ± 1.7

26.6 ± 2.0 c

28.2 ± 2.5 a

25.9 ± 2.0 b

0.00534

Femoral neck

0.31 ± 0.05

0.42 ± 0.11

0.79 ± 0.17

0.48 ± 0.20

0.69 ± 0.25

0.72 ± 0.21

0.043

Total hip

0.42 ± 0.05

0.57 ± 0.11

0.87 ± 0.17

0.62 ± 0.20

0.71 ± 0.25

0.86 ± 0.20

0.053

Lumbar spine5

0.14± 0.08

0.31 ± 0.16

0.44 ± 0.27

0.55 ± 0.30

0.51 ± 0.38

0.89 ± 0.31

0.16

Lean mass (kg)
Fat mass (kg)
aBMD Z-scores

Values are means ± SE or percentages. 1 P-values are based on ANOVA for continuous variables and chi-square test for categorical variables. Means
with similar superscripts are different using a post hoc Tukey test for multiple comparisons. 2 20% of cells have expected count less than 5. 3 No
differences among glucose intolerance groups using a post hoc Tukey test for multiple comparisons. 4 No differences among glucose intolerance groups
using a post hoc Tukey test for multiple comparisons; superscripts show differences based on contrasts. 5 Five fewer spine scans available than hip scans
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at 36 months; four in the normo/normoglycemic group and one in the pre/prediabetes group. Number of hip scans given. Abbreviations: T2D = type 2
diabetes; BMI = body mass index; aBMD = areal bone mineral density.
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Table 3.3. Baseline bone outcomes according to glycemic status.
Normoglycemia

Participants (n)

358

Pre-diabetes

51

p-trend 1

T2D
Model 1

Model 2

Model 3

21

Femoral neck
BMC (g)
BA (cm2)
2

aBMD (g/cm )

5.29 ± 0.04ab

5.47 ± 0.12a

5.30 ± 0.19b

0.37

0.02

0.15

5.83 ± 0.02

5.87 ± 0.06

5.76 ± 0.09

0.52

0.86

0.85

a

0.920 ± 0.03

b

0.47

0.01

0.08

47.96 ± 0.43

49.66 ± 1.14

48.41 ± 1.78

0.38

0.25

0.71

44.79 ± 0.24

44.85 ± 0.63

43.78 ± 0.99

0.60

0.52

0.33

a

1.106 ± 0.03

b

0.10

0.02

0.14

0.908 ± 0.01

ab

0.932 ± 0.02

Total hip
BMC (g)
2

BA (cm )
2

aBMD (g/cm )

1.069 ± 0.01

ab

1.107 ± 0.02

Lumbar spine 2
BMC (g)

76.66 ± 0.76

77.72 ± 2.00

78.64 ± 3.11

0.75

0.53

0.55

2

BA (cm )

70.27 ± 0.33

68.99 ± 0.88

69.54 ± 1.38

0.37

0.07

0.16

aBMD (g/cm2)

1.086 ± 0.01

1.124 ± 0.02

1.127 ± 0.03

0.13

0.21

0.42

Values are unadjusted mean + SE. Superscripts show means that were different based on model 2 using
contrasts for multiple comparisons. 1 Model 1 did not include any covariates; Model 2 adjusted for age,
age2, height, and population group; and Model 3 adjusted for age, age2, height, population group, and
total body fat and lean mass. 2 Two fewer spine scans available than hip scans at baseline; both were in
the normoglycemic group. Number of hip scans given. Abbreviations: T2D = type 2 diabetes; BMC =
bone mineral content; BA = bone area; aBMD = areal bone mineral density.
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Supplemental Table 3.1. Annual percent change in bone outcomes by glycemic status at baseline and follow-up.
Baseline:

Follow-Up:

Participants (n)

Normoglycemia

Normoglycemia

Normoglycemia

Pre-diabetes

Pre-diabetes

Normoglycemia

or Pre-diabetes
Pre-

diabetes

T2D

p-Value 1

T2D

T2D
Model 1

Model 2

Model 3

272

65

25

19

12

18

BMC

-0.54 ± 0.10

-0.23 ± 0.20

-0.62 ± 0.32

0.23 ± 0.37

-0.66 ± 0.46

-0.49 ± 0.38

0.30

0.24

0.27

BA

-0.15 ± 0.07

-0.04 ± 0.15

-0.51 ± 0.25

0.36 ± 0.28

0.31 ± 0.36

0.26 ± 0.29

0.11

0.11

0.09

aBMD

-0.39 ± 0.07

-0.17 ± 0.14ac

-0.11 ± 0.23b

-0.13 ± 0.27

-0.96 ± 0.33bc

-0.76 ± 0.27a

0.11

0.04

0.05

BMC

-0.52 ± 0.08

-0.45 ± 0.16

-0.26 ± 0.26

0.18 ± 0.30

-0.61 ± 0.38

-0.06 ± 0.31

0.19

0.37

0.20

BA

-0.40 ± 0.05

-0.48 ± 0.11

-0.11 ± 0.18

-0.13 ± 0.21

-0.45 ± 0.26

-0.22 ± 0.21

0.37

0.30

0.40

aBMD

0.12 ± 0.05

0.03 ± 0.10

-0.15 ± 0.17

0.31 ± 0.19

-0.17 ± 0.24

0.15 ± 0.20

0.18

0.39

0.27

BMC

0.34 ± 0.10

0.54 ± 0.21

0.40 ± 0.33

0.66 ± 0.39

1.56 ± 0.48

0.25 ± 0.39

0.22

0.42

0.50

BA

-0.18 ± 0.06

-0.13 ± 0.12

-0.03 ± 0.19

0.03 ± 0.22

0.76 ± 0.27

-0.34 ± 0.22

0.03

0.06

0.15

aBMD

0.51 ± 0.08

0.67 ± 0.15

0.42 ± 0.25

0.62 ± 0.29

0.80 ± 0.36

0.59 ± 0.29

0.90

0.54

0.59

Femoral neck

Total hip

Lumbar spine2

Values are unadjusted annual percent change from baseline in bone mineral status. Superscripts show means that were different based on model 2 using
contrasts for multiple comparisons. 1 Model 1 did not include any covariates; Model 2 adjusted for age, age2, height, and population group; and Model
3 adjusted for age, age2, height, population group, initial bone measures, baseline total body fat and lean mass, and annual percent change in total
body fat and lean mass. 2 Five fewer spine scans available than hip scans at three-year; four in the normo/normoglycemic group and one in the
pre/prediabetic group. Number of hip scans given. Abbreviations: T2D = type 2 diabetes; BMC = bone mineral content; BA = bone area; aBMD =
areal bone mineral density.
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Men Aged 20-66 years
(n=544)
Excluded (n=114*)
No glucose measures at baseline (n=12)
No TB scan at baseline (n=23^)
Study withdraw or no glucose at 36 months (n=79)
(n=430)

Normoglycemia
Baseline analysis (n=358)

No DXA scans at follow-up (n=13)
Follow-up analysis (n=345)
Remained normoglycemic (n=272)^#
Progressed to pre-diabetes (n=65)
Progressed to T2D (n=8)^

Pre-diabetes
Baseline analysis (n=51)

No DXA scans at follow-up (n=3)
Follow-up analysis (n=48)
Remained pre-diabetic (n=19) #
Reverted to normoglycemia (n=25)
Converted to T2D (n=4)

T2D
Baseline analysis n=21

No DXA scans at follow-up (n=3)
Follow-up analysis (n=18)
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Figure 3.1. Flowchart of participants included in the baseline and rate of change analyses. * Individuals who were unable to
be categorized into glycemic groups were excluded. ^ Number of hip scans are shown, there were two fewer spine scans
available than hip scans at baseline (both were in the normo/normoglycemic group). # Number of hip scans are shown, there
were five fewer spine scans available than hip scans at three-year (four in the normo/normoglycemic group and one in the pre/pre-diabetes group). Abbreviations: DXA, dual-energy X-ray absorptiometry; T2D, type 2 diabetic.

Annual % Change in FN aBMD

99

0.0

c

-0.1
-0.2

a,b

-0.3
-0.4
-0.5
-0.6
-0.7

a

-0.8
-0.9
-1.0

b,c

Figure 3.2. Marginal mean annual percent change in FN aBMD according to glycemic groups adjusted for age, age2, height,
population group, and total body fat and lean mass. Means with similar letters are significantly different from each other.
Abbreviations: FN = femoral neck; aBMD = areal bone mineral density; T2D = type 2 diabetes.
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Figure 3.3. The relationship between baseline hip aBMD and lean mass varied by
glycemic status (glycemic status-by-lean mass interaction, p = 0.004). Abbreviations:
aBMD = areal bone mineral density; T2D = type 2 diabetes.
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Abstract
Objective: The transition from pre-diabetes to normoglycemia leads to improved plasma
blood lipids, while conversion from normoglycemia and pre-diabetes to type 2 diabetes
(T2D) results in worsening plasma blood lipids. The aim of the current study was to
explore the associations of cross-sectional and longitudinal changes in glycemic status
with baseline and changes in fasting blood lipids.
Methods: Data from the South Dakota Rural Bone Health Study are used for the current
analyses. Participants were 300 men, aged 20 to 66 years, who participated in the South
Dakota Rural Bone Health Study and completed baseline assessments and 192 men who
completed a 36-mo follow-up assessment and had fasting blood glucose and lipid,
anthropometrics, body composition, and dietary intake. Pre-diabetes was defined by
fasting plasma glucose 100 to 125 mg/dL, and T2D was determined by self-reported
T2D, current use of the anti-diabetic drug (insulin/oral hypoglycemic agents), or a fasting
serum glucose concentration (≥126 mg/dL) at baseline or follow-up. Multivariate
analyses were used to estimate marginal means of baseline and change in plasma lipid
outcomes among different categories of glycemic status controlling for covariates.
Results: T2D, but not pre-diabetes, was positively associated with triglyceride (beta
coefficient = 0.29, p = 0.003), cardio risk ratio (beta coefficient = 0.64, p = 0.01), and
atherogenic index of plasma (beta coefficient = 0.10, p = 0.01), and negatively associated
with low-density lipoprotein (beta coefficient = -13.92, p = 0.05). No significant
association was observed between changes in glycemic status and changes in lipid
profile.
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Conclusion: T2D men had an atherogenic lipid profile and are at increased risk for
cardiovascular disease.
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Introduction
Pre-diabetes and type 2 diabetes (T2D) are major public health challenges. The
prevalence of prediabetes and T2D in US adults aged ≥ 20 years reported by the National
Health and Nutrition Examination Survey has increased: pre-diabetes from 59.9% in
1999-2004 to 78.5% in 2011-2014 [1] and T2D from 8.8% in 1999-2000 to 11.7 % in
2013-2014 [2].
Dyslipidemia, defined as having one or more of the following criteria: highdensity lipoprotein cholesterol (HDL-C) < 40 mg/dL, non-HDL-C ≥ 160 mg/dL,
triglyceride (TG) ≥150 mg/dL, or self-reported taking lipid-lowering medications, is
estimated to occur in 51.2% of adults with pre-diabetes [1] and 77.0% of adults with T2D
[3]. The underlying mechanism for dyslipidemia in pre-diabetes and T2D is the presence
of insulin resistance contributing to the diminished activity of lipoprotein lipase and
elevated activity of hepatic TG lipase, which in turn increases TG concentrations and
decreases HDL-C concentrations [4]. Despite abundant cross-sectional data on
conventional lipid parameters in men with pre-diabetes and T2D, findings are
inconclusive, with some cross-sectional studies reporting differences in total cholesterol
(TC), HDL-C, low-density lipoprotein cholesterol (LDL-C), and TG among men with
different glycemic status while other studies do not [5-9]. Recently, the cardiac risk ratio
(CRR; TC/HDL-C) and the atherogenic index of plasma (AIP; log [TG/HDL-C]) have
been introduced and used as atherogenic indices and reflect the balance between
atherogenic lipids and antiatherogenic lipoproteins. Some studies have evaluated lipid
ratios in pre-diabetes and T2D and revealed greater CRR and AIP in pre-diabetic and
T2D individuals than in their normoglycemic counterparts [5,10,11], while other studies
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have shown no difference in CRR and AIP between T2D and normoglycemic individuals
[12,13].
Inconsistent findings from previous cross-sectional studies suggest extending
knowledge on the timing of the impact of glycemic status on lipid profile and ratios. Only
two prospective randomized trials have examined changes in individual lipid measures in
relation to changes in glycemic status over time. Conversion from pre-diabetes to T2D
resulted in increased TC and TG and decreased HDL-C [14,15]. Two other trials found
no change from baseline in CRR and AIP among adults with T2D who received placebo
[12,16]. To the best of our knowledge, longitudinal observational studies have not been
conducted to evaluate the impact of changes in glycemic status on changes in lipid
measures and ratios over time. The aim of this study was to determine the effects of
cross-sectional and longitudinal changes in glycemic status on baseline and changes in
lipid biomarkers and CRR and AIP ratios.
We hypothesized that 1) pre-diabetic and T2D men would have greater TC, LDL-C,
TG, CRR, and AIP and lower HDL concentrations than normoglycemic men at baseline;
2) TC, LDL-C, TG, RCC, and AIP concentrations would increase, and HDL
concentrations would decrease, in normoglycemic men who developed pre-diabetes or
T2D; and 3) TC, LDL-C,TG, CRR, and AIP concentrations would decrease, and HDL
concentrations would increase, in pre-diabetic men who reverted to normoglycemia
compared to prediabetic men who remained pre-diabetic.
Methods
Study population
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The South Dakota Rural Bone Health Study (SDRBHS) is a population-based
longitudinal study originally designed to study the effect of lifestyle factors on bone and
body composition. The design and recruitment of the study participants have been
previously published [17]. In brief, a total of 1,271 men and women aged 20 to 66 years
from eight counties in eastern South Dakota were recruited to participate in the study.
The current analysis is limited to 544 men, comprising 410 men who farmed at least 75%
of their lives (rural) and 134 men who never lived on an active farm (non-rural). The
rural population was divided into Hutterites and non-Hutterites. A Hutterite is an
individual of Hutterite descent who lived on a Hutterite colony. Hutterites are an
Anabaptist religious group who believes in isolated communal living and self-sufficiency
through an agriculturally advanced lifestyle. Non-Hutterites were randomly selected from
the eight-county region as described elsewhere [17].
Among 544 men who completed the baseline visit between 2001 and 2004, 244 men
were excluded at baseline for the following reasons: no blood glucose or fasting lipid
concentrations (n=225), missing body composition measurements (n=11), use of lipidlowering medications (n=7), and no dietary intake data (n=1) (Figure 4.1). The follow-up
visit occurred three years after the baseline visit. At follow-up we excluded men with no
blood glucose or fasting lipid concentrations (n=67) or body composition (n=41)
measurements at follow-up (Figure 4.1). After baseline and follow-up exclusions of
participants, 300 and 192 men were included in the baseline and follow-up analyses,
respectively. The study was approved by the South Dakota State University Institutional
Review Board, and informed consent was obtained from all participants.
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Assessment of pre-diabetes and T2D
According to the American Diabetes Association (ADA) diagnostic criteria,
individuals with a fasting blood glucose of 100 to 125 mg/dL were classified as having
pre-diabetes [18]. T2D was determined by one of the following criteria: self-reported
diabetes, current use of an anti-diabetic drug (insulin or oral hypoglycemic agents), or a
fasting blood glucose concentration ≥126 mg/dL [18]. The same criteria for the diagnosis
of pre-diabetes and T2D were applied at both the baseline and three-year visits. Glucose
was measured at baseline and follow-up. Attempts were made to obtain fasting blood
samples, and measurements were made in the field from a sample of venous whole blood
(EDTA) using an Accu-Check Advantage glucometer (Roche Diagnostics, Indianapolis,
IN).
Measurement of plasma lipid
Plasma samples were collected after an overnight fast for measurements of TC, HDLC, and TG. Blood samples were sent to the Clinical Laboratories of the Midwest (Sanford
Health Systems, Sioux Falls, SD) for analyses. LDL-C was computed using the
Friedewald formula for men with TG concentrations <400 mg/dL. Therefore, LDL-C was
not calculated for men with TG concentrations >400 mg/dL (n=21 at baseline and n=14
at follow-up visits). The coefficients of variation of TC, HDL-C, and TG were 1% [19].
Lipid ratios were calculated as follows: CRR = TC/HDL-C [20] and AIP = log
(TG/HDL-C) [11]. The normal ranges for CRR and AIP are <4 to 1 and -0.3 to 0.1,
respectively [21,22].
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Assessment of covariates
Interviewer-administered questionnaires were used to obtain information on
demographics, medication use, medical history, and dietary intake. Information on the
use of prescription medications and the presence of chronic diseases were collected at
both visits. Participants were asked to report if they were currently taking cholesterollowering drugs and any prescribed medications. If yes, they provided information about
drugs. Dietary intake was assessed quarterly at both baseline and follow-up visits using
24-hour dietary recalls. Trained interviewers administered 24-hour dietary recalls, and
dietary recall data were analyzed for macronutrients using Nutritionist Pro software
(version 2.3.1, 2004, First DataBank, Inc., San Bruno, CA). For foods not available in the
Nutritionist Pro software, the nutrient composition of the foods was obtained from
entering the recipes. Nutrient intakes at baseline were the averages of the baseline, 3- and
6-month recalls and the measures at the three-year visit were the averages of the 30-, 33and 36-month recalls.
Body height and weight were measured in lightweight clothes without shoes using
calibrated stadiometer and scale. Standing height was measured to the nearest 0.5 cm in
duplicate with a Seca stadiometer (Chino, CA). A third measurement was taken if the
discrepancy between the duplicate height measurements was more than 0.5 cm. Weight
was measured to the nearest 0.1 kg with a Seca digital scale (Model 770, Chino, CA).
Body composition was assessed using dual-energy x-ray absorptiometry (DXA)
(Discovery, Software Version 12.01, Hologic, Waltham, MA). A total body scan was
completed with boundaries for the various anatomical regions set according to
manufacturer’s specifications. The step phantom scan for body composition calibration
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was completed weekly as suggested by the manufacturer. Prior to DXA measurements,
the Hologic Spine Phantom was completed for quality control. All scans were analyzed
by the same ISCD-certified technician. Scan results were deleted for obese participants
with an equivalent epoxy thickness greater than 12 inches, as determined by the Hologic
software, per manufacturer recommendations (n=16 men: n=7 Hutterite, n=4 rural, n=5
non-rural). DXA-derived measurements of the total body and trunk fat mass were
determined from the whole-body scans. Percent of total body (TB) fat in the trunk was
computed as trunk fat mass divided by total body fat mass times 100. Our coefficient of
variation for total body fat in 15 adults (1 male) using triplicate scans with repositioning
between each scan is <1.5%.
Statistical analysis

Analysis of variance and Fisher’s exact test for categorical variables were used to
determine statistical significance in baseline characteristics. Characteristics were
expressed as a mean ± standard error (SE) for variables with a normal distribution,
geometric mean (95% confidence interval [CI]) for log-transformed variables (TG), and
proportions of participants for categorical variables. Multiple regression models were
used to estimate marginal means ± SE for baseline lipid indices and absolute changes in
outcome measures by different categories of glycemic status. Differences in marginal and
geometric means among glycemic groups were evaluated using post hoc contrast tests.
We previously reported that demographic and anthropometric characteristics, as well as
macronutrient intakes were cross-sectionally associated with lipid measures and ratios
[19]; therefore, these previously identified covariates were included in the linear models.
The baseline statistical model was adjusted for age, height, weight, percent of TB fat in
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the trunk, percent of calories from carbohydrates, and percent of calories from fat. The
longitudinal model was adjusted for the same variables included in the baseline model as
well as absolute changes in weight, use of lipid-lowering medication at the three-year
visit, and baseline measure of the specific blood lipid being modeled. Absolute changes
in percent of TB fat in the trunk, percent of calories from carbohydrates, and percent of
calories from fat were non-significant; hence, they were excluded from all longitudinal
models. The assumptions of linearity, normality, and homoscedasticity were evaluated
visually to ensure no violation of assumptions. The presence of collinearity was assessed
using the variance inflation factor. All analyses were performed using JMP software
(version 13, SAS Institute, Cary, NC) and the statistical significance level was set at p <
0.05 (2-tailed).

Results

Baseline characteristics

Of the 300 men at baseline, 59 (19.7%) and 17 (5.7%) had pre-diabetes and T2D,
respectively. Overall, the mean (±SE) age was 40.3 ± 0.7 years, weight was 91.2 ± 0.9
kg, BMI was 29.0 ± 0.3 kg/m2, and percent of TB fat in the trunk region was 50.3 ±
0.4%. Pre-diabetic and T2D men were older and had greater body weight, BMI, and
percent of TB fat in the trunk than normoglycemic men. Percent of calories from
carbohydrates was higher among normoglycemic men compared to T2D men (Table 4.1).

Baseline characteristics of men who completed the three-year follow-up visit are
presented in Table 4.2. Among the 142 normoglycemic men at follow-up, 95 (66.9%)
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remained normoglycemic, 44 (31%) became pre-diabetic, and 3 (2.1%) developed T2D.
Of the 41 pre-diabetic men over a three-year period, 18 (43.9%) remained pre-diabetic,
19 (46.3%) reverted to normoglycemia, and 4 (9.8%) converted to T2D. Normoglycemic
men who remained normoglycemic throughout the study were younger and had lower
body weight and BMI than men with pre-diabetes and T2D and normoglycemic or prediabetic men who developed T2D.

Cross-sectional analysis

Table 4.3 presents both unadjusted and adjusted mean lipid measures and ratios
according to the glycemic status at baseline. Unadjusted TC concentrations were higher
in the T2D group than in the normoglycemic group, but differences disappeared after
adjustment for covariates. The unadjusted mean of LDL-C concentrations did not vary
among the glycemic groups, but it was higher in the normoglycemic group than in the
T2D group after adjusting for age, height, weight, percent of TB fat in the trunk, percent
of calories from carbohydrates, and percent of calories from fat. This may be explained in
part by a higher percent of men with T2D have TG>400 mg/dl and thus no LDL-C
measurements (see Table 4.3 footnote). HDL-C concentrations were similar among
glycemic groups in both unadjusted and adjusted models. TG, CRR, and AIP were lower
in the normoglycemic men compared to men with T2D (both unadjusted or adjusted
models).

Longitudinal analysis
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Table 4.4 presents unadjusted and adjusted mean changes in lipid biomarkers and
ratios according to the baseline glycemic status and changes in glycemic status during the
follow-up period. Unadjusted analyses revealed significant changes in TC and LDL-C
concentrations across various categories of glycemic status at follow-up, but after
adjusting for covariates there were no differences among categories in changes in TC and
LDL-C (Table 4.4). Additionally, there were no differences among categories of
glycemic status either before or after adjusting for covariates in TG, CRR or AIG.
Results did not differ if 24 participants who were taking cholesterol-lowering
medications at the three-year visit were excluded.

Discussion

With respect to the first hypothesis, pre-diabetic men had similar plasma blood
lipids as normoglycemic men. T2D men had greater TG, CRR, and AIP and lower LDLC concentrations compared to their normoglycemic counterparts, but there were no
differences in TC and HDL-C concentrations. This is the first observational longitudinal
study to evaluate the association of changes in glycemic status with changes in plasma
blood lipids. Changes in glycemic status were not observed to be associated with changes
in lipid profiles over a three-year period once covariates were included in the analyses.

In contrast to earlier findings [5,23-26], prediabetes, as defined in our study, was
not associated with the lipid profiles that differed from normoglycemic men. There is a
possible explanation for this result. Fasting blood glucose in our study is at the lower end
of the pre-diabetes threshold. Some investigators have reported an association between
impaired fasting glucose and increased TC, TG, and LDL-C concentrations [5,23], while
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impaired glucose tolerance is associated with a more atherogenic lipid profile
(hypertriglyceridemia, increased small dense LDL, and low HDL-C) [5,23,24,27]. This
can be explained by different pathophysiology between impaired fasting glucose and
impaired glucose tolerance. Patients with impaired fasting glucose have insulin resistance
in the liver and normal insulin sensitivity in the muscle, whereas patients with impaired
glucose tolerance have insulin resistance in the skeletal muscle and milder insulin
resistance in the liver [28]. In the presence of impaired fasting glucose, very low-density
lipoprotein (VLDL) is elevated as a result of increased hepatic TG lipoprotein synthesis.
This leads to increased production and secretion of hepatic apo B-100 resulting in
hypertriglyceridemia [4]. Hyperinsulinemia promotes free fatty acid flux to the liver by
suppressing liver adipocyte lipolysis resulting in an increase in hepatic secretion of
VLDL leading to hypertriglyceridemia. In addition, a decrease in lipoprotein lipase
activity of adipose tissue contributes to reduce VLDL breakdown and elevations in TG
concentrations [4].

In the state of impaired glucose tolerance, impaired fatty acid uptake and
oxidation in skeletal muscle leads to the accumulation of free fatty acids and lipids that
promote hepatic synthesis and secretion of TG-enriched VLDL particles. These particles
are exchanged for TG-enriched LDL and HDL particles by cholesterol ester transfer
protein [29,30]. Hepatic TG lipase hydrolyzes TG-enriched LDL and HDL particles and
accelerates clearance of LDL and HDL particles resulting in an increase in small dense
LDL particles and a decrease in concentration of HDL-C [30]. Our results agree with
previous cross-sectional studies that have reported a positive association between T2D
and TG, CRR, and AIP [5,11,25].
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In contrast with the two previous clinical studies, the current study found that
changes in lipid profile among men who became pre-diabetic or T2D did not differ from
those who remained pre-diabetic and normoglycemic during the follow-up period.
Goldberg et al. [15] reported that TG concentration increased, and HDL-C concentration
decreased in middle-aged adults who progressed to pre-diabetes over a one-year followup. They also reported that reversion from pre-diabetes to normoglycemia was associated
with increases in HDL-C and LDL-C concentrations and decreases in TG concentration
[15], suggesting that regression from pre-diabetes to normoglycemia may lead to reduced
cardiovascular risk. Reductions in HDL-C and LDL-C concentrations and increases in
TC and TG concentrations were observed in pre-diabetic adults who converted to T2D
[14,15]. Findings from our study are consistent with a previous study that reported no
changes in TC, HDL-C, and TG concentrations among pre-diabetic men who reverted to
normoglycemia or remained pre-diabetic throughout the study [14].

Study population and design, as well as methodological limitations, may
contribute to contradictory findings regarding the effects of changes in glycemic status on
changes in blood lipid levels. We enrolled men with a wide age range (20 to 66 years) in
comparison to clinical trials that included only middle-aged and older adults. Our
diagnosis of pre-diabetes and T2D was based on fasting plasma glucose, a previous
diagnosis of diabetes, or current prescribed diabetic medications, while the clinical trials
used a combination of fasting plasma glucose and oral glucose tolerance tests to confirm
the diagnosis of pre-diabetes and T2D.
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Our study has some limitations. The major limitation of this study is the small
number of T2D cases at follow-up. There were only seven men who developed T2D and
nine men who were T2D throughout the study. The sample size needed to reach 5%
significance with 80% power at the difference currently observed is 21 in the 2TD group.
Study participants were predominantly white men; therefore, the results cannot be
generalized to other races or women. With a small sample size and including only men in
the study, caution must be applied, as the findings need to be confirmed by future studies.

The present study has several strengths. The SDRBHS is a population-based,
longitudinal study and fasting blood glucose and lipids were measured at baseline and
follow-up visits which enabled us to examine the association of changes in glycemic
status with changes in lipid profile over a three-year period. To the best of our
knowledge, this is the first population-based study with diverse lifestyles addressing
changes in lipid measures across various categories of abnormal glycemic status at
follow-up. Dietary recalls were administered quarterly and the average of three recalls at
baseline (baseline, 3- and 6-month) and follow-up (30-, 33- and 36-month) was used to
estimate nutrient intake.

Conclusion

In conclusion, we found that no differences in plasma blood lipids were noted
between pre-diabetes and normoglycemia. T2D men had lower LDL-C and greater TG,
CRR, and AIP than normoglycemic men. Changes in glycemic status were not associated
with changes in lipid profile before or after excluding participants taking lipid-lowering
therapy from analyses. The findings of this study indicate that T2D men had a more
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atherogenic lipid profile than their normoglycemic counterparts. The current study
contributes to existing knowledge of glycemic effect on lipid profile. Large longitudinal
studies could provide more definitive evidence on change in glycemic status in relation to
changes in blood lipids.
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Table 4.1. Baseline characteristics of men by glycemic status at baseline.
Normoglycemia

Pre-diabetes

T2D

p-Value
1

Participants (n)
Age (years)

224
38.0 ± 0.8

59
ab

45.5 ± 1.6

17
b

52.2 ± 2.9a

<0.001

0.53

Anthropometrics
Height (cm)

177.5 ± 0.4

177.5 ± 0.8

175.7 ± 1.5

Weight (kg)

89.2 ± 1.0

ab

96.9 ± 1.9

b

99.0 ± 3.6

a

<0.001

28.3 ± 0.3

ab

30.8 ± 0.5

b

32.0 ± 1.1

a

<0.001

2

BMI (kg/m )
Body composition

49.1 ± 0.4ab

53.1 ± 0.8b

56.9 ± 1.6a

<0.001

% kcal CHO

42 ± 1a

40 ± 1

37 ± 2a

0.01

% kcal fat

39 ± 0

%TB fat in trunk
Dietary intake

Fasting glucose
(mg/dL)

86.0 ± 1.1
(54-99)

40 ± 1
ab

107.3 ± 2.1
(100-125)

41 ± 2
b

160.5 ± 3.9

0.26
a

<0.001

(82-310)

Data are presented as unadjusted mean ± SE (range).1 P value is based on ANOVA using a post hoc Tukey
test for multiple comparisons. Means with similar superscripts are different. Abbreviations: T2D, type 2
diabetes; TB, total body; %kcal CHO, percent of calories from carbohydrates; %kcal fat, percent of calories
from fat.
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Table 4.2. Baseline characteristics of men completing a three-year follow-up by glycemic status at baseline and follow-up.
Baseline:
Follow-Up:
Participants (n)
Age (years)
Anthropometric measures
Height (cm)
Weight (kg)
BMI
Body composition
%TB fat in trunk
Daily intake
% kcal CHO
% kcal fat
% Cholesterol-lowering drug2
Fasting glucose (mg/dL)

Normoglycemic

Pre-diabetic

Normoglycemic
or Pre-diabetic

T2D
p-Value 1

Normoglycemic

Pre-diabetic

Normoglycemic

Pre-diabetic

T2D

T2D

95
35.9 ± 1.2abc

44
41.1 ± 1.7d

19
43.7 ± 2.6

18
46.8 ± 2.7a

7
52.1 ± 4.3b

9
53.1 ± 3.8cd

<0.001

177.4 ± 0.6
87.3 ± 1.3abc
27.8 ± 0.4abc

177.0 ± 0.9
90.2 ± 2.0
28.8 ± 0.6d

178.2 ± 1.4
94.2 ± 3.0
29.7 ± 0.9e

176.5 ± 1.4
97.1 ± 3.1a
31.2 ± 0.9a

172.9 ± 2.3
104.3 ± 4.9b
34.8 ± 1.5bde

177.2 ± 2.0
100.4 ± 4.3c
32.0 ± 1.3c

0.49
<0.002
<0.001

48.5 ± 0.7ab

51.3 ± 1.0

52.0 ± 1.5

55.5 ± 1.5a

51.6 ± 2.4

57.9 ± 2.1b

<0.001

42 ± 1
42 ± 1
40 ± 2
39 ± 2
39 ± 3
38 ± 3
0.30
38 ± 1
39 ± 1
41 ± 1
40 ± 1
40 ± 2
40 ± 2
0.39
11.6
9.1
0.0
5.6
42.9
55.6
0.001
86.0 ± 1.6a
86.7 ± 2.4bc
104.5 ± 3.6c
108.8 ± 3.7b
98.6 ± 5.9
158.6 ± 5.2a
<0.001
(65-99)
(54-99)
(100-114)
(101-123)
(79-112)
(82-310)
1
Data are presented as an unadjusted mean ± SE (range). P value is based on ANOVA using a post hoc Tukey test for multiple comparisons and
Fisher’s exact test for categorical variables. Means with similar superscripts are different.2 The percentage of men (n=24) who were taking cholesterollowering treatment during a follow-up period of three years. Abbreviations: T2D, type 2 diabetes; TB, total body; %kcal CHO, percent of calories from
carbohydrates; %kcal fat, percent of calories from fat.
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Table 4.3. Mean of baseline plasma lipid biomarkers and ratios by glycemic status in
men.
p-Value 1
Normoglycemia
Pre-diabetes
T2D
Participants (n)
224
59
17
Lipid profile (mg/dL)
TC
Crude
191.5 ± 3.1a
193.7 ± 6.1
222.8 ± 11.3a
0.03
Adjusted
194.4 ± 3.1
186.6 ± 6.1
206.7 ± 11.5
0.23
LDL-C2
Crude
116.3 ± 2.6
115.9 ± 5.1
108.7 ± 10.5
0.78
Adjusted
118.6 ± 2.5a
110.7 ± 5.0
93.8 ± 10.5a
0.05
HDL-C
Crude
44.6 ± 0.8
43.2 ± 1.5
38.8 ± 2.8
0.12
Adjusted
44.1 ± 0.7
44.5 ± 1.4
40.8 ± 2.7
0.45
TG34
Crude
169.7 ± 15.1a
181.8 ± 29.3
415.4 ± 54.6a
<0.001
a
156.9 ± 28.0
363.0 ± 52.7a
0.01
Adjusted
180.2 ± 14.2
Lipid ratios
CRR
Crude
4.6 ± 0.1a
4.7 ± 0.2
6.1 ± 0.4a
0.001
Adjusted
4.7 ± 0.1a
4.4 ± 0.2
5.5 ± 0.4a
0.03
AIP
1.4
1.6a
<0.001
Crude
1.3a
a
Adjusted
1.3
1.3
1.5a
0.02
Data are presented as mean ± SE. 1 P value was from linear regression models. The crude model was
unadjusted for covariates. The adjusted model included age, height, weight, %kcal CHO, %kcal fat, and
%TB fat in trunk. 2 LDL-C was not calculated for men with TG ≥ 400 mg/dL (n=21): 6.3%, 5.1% and
23.5% of normoglycemic, pre-diabetic, and T2D men had TG > 400 mg/dl, respectively (p=0.05). 3 TG
was log transformed for analysis, but it is presented in the table in the non-transformed form.
4
Excluding three participants with TG ≥1573 mg/dL from the analysis resulted in for group differences
(unadjusted P<0.001 and adjusted P=0.04). The mean TG concentration was 161.7 ± 7.8 for
normoglycemic group, 163.5 ± 15.2 for pre-diabetic group, and 251.3 ± 29.5 for T2D group.
Abbreviations: T2D, type 2 diabetes; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol;
HDL-C, high density lipoprotein cholesterol; TG, triglyceride, CRR, cardio risk ratio (TC/HDL-C); AIP,
atherogenic index of plasma (log (TG/HDL-C)).
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Table 4.4. Mean changes in plasma lipid biomarkers and ratios by change in glycemic status.
Baseline:
Follow-Up:

Normoglycemic

Pre-diabetic

Normoglycemic

Pre-diabetic

Normoglycemic

Pre-diabetic

Normoglycemic
or Pre-diabetic
T2D

T2D

95

44

19

18

7

9

192.5 ± 4.8
-1.8 ± 3.5a
-17.9 ± 3.9

190.5 ± 7.0
-3.3 ± 5.2
-22.1 ± 4.9

190.5 ± 10.7
3.7 ± 7.9
-16.8 ± 7.2

193.0 ± 10.9
-1.2 ± 8.1
-21.2 ± 7.3

233.4 ± 17.6
-24.0 ± 13.0
-12.3 ± 11.3

207.6 ± 15.5
-40.6 ± 11.4a
-35.4 ± 9.4

0.29
0.02
0.55

116.4 ± 4.4
1.2 ± 3.2a
-14.5 ± 4.2

116.9 ± 6.3
-2.1 ± 4.6
-21.5 ± 5.2

111.2 ± 9.6
11.5 ± 7.0b
-12.3 ± 7.1

115.2 ± 9.6
-0.4 ± 7.0
-21.3 ± 7.0

152.5 ± 16.6
-22.5 ± 12.2b
-16.4 ± 11.4

111.0 ± 15.3
-26.0 ± 11.3a
-29.1 ± 9.9

0.40
0.04
0.50

43.4 ± 1.1
2.1 ± 0.9
1.2 ± 1.1

42.8 ± 1.7
0.8 ± 1.3
0.1 ± 1.5

41.9 ± 2.6
-0.2 ± 2.1
-1.9 ± 2.2

44.7 ± 2.6
-0.7 ± 2.1
-0.9 ± 2.2

40.9 ± 4.2
3.4 ± 3.4
2.5 ± 3.4

39.4 ± 3.7
3.7 ± 3.0
3.6 ± 2.9

0.86
0.65
0.54

218.0 ± 32.9
140.8 ± 18.4b
-51.0 ± 29.4
-5.1 ± 22.8

200.6 ± 50.1
200.6 ± 27.4
-57.6 ± 44.7
-7.3 ± 32.8

165.7 ± 51.5
165.7 ± 28.2b
-0.3 ± 45.9
-1.2 ± 33.2

213.7 ± 82.5
213.7 ± 45.2
-50.7 ± 73.6
-8.8 ± 51.3

297.1 ± 72.8
297.1 ± 39.8a
-123.0 ± 64.9
-67.7 ± 43.0

0.08
0.008
0.52
0.79

4.7 ± 0.2
-0.2 ± 0.2
-0.5 ± 0.2

4.8 ± 0.4
-0.1 ± 0.3
-0.2 ± 0.3

4.5 ± 0.4
0.1 ± 0.3
-0.4 ± 0.3

5.7 ± 0.6
-1.0 ± 0.5
-0.4 ± 0.5

5.6 ± 0.5
-1.6 ± 0.5
-1.4 ± 0.4

0.41
0.06
0.21

1.3 ± 0.04
-0.02 ± 0.03
-0.01 ± 0.03

1.4 ± 0.06
-0.09 ± 0.05
-0.02 ± 0.04

1.3 ± 0.06
-0.02 ± 0.05
-0.02 ± 0.05

1.4 ± 0.09
-0.08 ± 0.08
-0.001 ± 0.07

1.5 ± 0.08
-0.14 ± 0.07
-0.08 ± 0.06

0.20
0.57
0.82

T2D

p-Value
1

Participants (n)
Lipid profile (mg/dL)
TC
Crude baseline
Crude change
Adjusted change
LDL-C§
Crude baseline
Crude change
Adjusted change
HDL-C
Crude baseline
Crude change
Adjusted change
TG¶

Crude baseline
168.8 ± 22.4
Crude baseline‡
160.6 ± 12.3a
Crude change*
-17.9 ± 20.0
Adjusted change*
-6.8 ± 17.3
Lipid ratios
CRR
Crude baseline
4.7 ± 0.2
Crude change
-0.3 ± 0.1
Adjusted change
-0.4 ± 0.2
AIP
Crude baseline
1.3 ± 0.03
Crude change
-0.05 ± 0.02
Adjusted change
-0.05 ± 0.02
Data are presented as mean ± SE.
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†

P values for crude mean at baseline and in change using ANOVA with no covariates. P values for adjusted change were from linear regression models
adjusting for age, height, weight, percent of calories from carbohydrates, percent of calories from fat, percent of TB fat in the trunk, use of
cholesterol-lowering drug at 36-month (yes/no), change in body weight, and baseline measure of the specific blood lipid being modeled.
§
LDL-C was not calculated for men with TG ≥ 400 mg/dL (n=16).
¶
TG was log transformed for analysis, but it is presented in the table in the non-transformed form.
‡
Excluding three participants (one normoglycemia/normoglycemia and two normoglycemia/pre-diabetes) with TG ≥936 mg/dL from the analysis
resulted in group differences.
*
Excluding one participant (one normoglycemia/normoglycemia) with ≥936 mg/dL from the analysis did not alter the conclusions.
Abbreviations: T2D, type 2 diabetes; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol;
TG, triglyceride; CRR, cardio risk ratio (TC/HDL-C); AIP, atherogenic index of plasma (log (TG/HDL-C)).
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Men Aged 20-66 years
(n=544)

Excluded at baseline (n=244):
No glucose or fasting lipid profile (n=225)
No body composition (n=11)
Taking lipid-lowering medication (n=7)
No dietary intake (n=1)

Baseline analysis (n=300)

Normoglycemia (n=224)

Pre-diabetes (n=59)

Excluded at follow-up (n=82):
No glucose or fasting lipids (n=55)
No body composition (n=27)

Excluded at follow-up (n=18):
No glucose or fasting lipids (n=8)
No body composition (n=10)

Included at follow-up analysis (n=142)

Included at follow-up analysis (n=41)

Remained normoglycemic (n=95)

Remained pre-diabetic (n=18)

Progressed to pre-diabetes (n=44)

Reverted to normoglycemia (n=19)

Progressed to T2D (n=3)

Progressed to T2D (n=4)

Figure 4.1. Flowchart of participants. Abbreviations: T2D, type 2 diabetes.

T2D (n=17)

Excluded at follow-up (n=8):
No glucose or fasting lipids (n=4)
No body composition (n=4)
Included at follow-up analysis (n=9)
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CHAPTER 5: Discussion and Overall Conclusions
In this dissertation, we aimed to investigate the associations of baseline and
changes in glycemic status with baseline and changes in body composition, bone health,
and lipid profile in men aged 20 to 66 years from South Dakota Rural Bone Health Study.
Chapter one introduces readers to the epidemiology and pathophysiology of pre-diabetes
and type 2 diabetes as well as the effect of baseline glycemic status on baseline and
changes in total and regional body composition, bone mass at FN, hip, and spine (aBMD,
BMC, and bone area), and lipid profile.
Chapter two studied the associations of baseline and changes in glycemic status
with baseline and changes in body composition over a three-year follow-up. Our findings
suggest that cross-sectional associations indicated that no differences in total and regional
body composition were observed among glycemic groups. Changes in glycemic status
were associated with changes in TB FM and LM and appendicular LM. Conversion from
normoglycemia to pre-diabetes was associated with loss of TB and appendicular LM.
Progression from normoglycemia or pre-diabetes to type 2 diabetes correlated with
greater losses of TB and appendicular LM. Type 2 diabetes had effects on greater losses
of TB and appendicular LM and greater gains in TB FM over a three-three period.
In Chapter three, we focused on the effects of baseline and changes in glycemic
status on baseline and changes in bone mass. The impact of baseline glycemic status on
aBMD and BMC at multiple skeletal sites was not significant after adjustment for body
composition differences. Associations of hip aBMD and BMC and spine aBMD with LM
was attenuated in pre-diabetic men as compared to normoglycemic and T2D men. The
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transition from normoglycemia or pre-diabetes to T2D was associated with a greater loss
of FN aBMD. T2D was also associated with a greater loss of FN aBMD.
Chapter four investigated the associations of cross-sectional and longitudinal
changes in glycemic status with baseline and changes in plasma blood lipids. Our results
suggested that there was no association between lipid profile and pre-diabetes. T2D men
had greater TG, CCR, and AIP than their normoglycemic counterparts. No significant
association was observed between changes in glycemic status and changes in lipid
profile. The main findings of this dissertation are that the changes in glycemic status over
time have adverse effects on body composition and bone health. The changes in glycemic
status should be further explored in relation to changes in blood lipid.
In conclusion, these findings provide new insights regarding the associations of
cross-sectional and longitudinal changes in glycemic status with baseline and changes in
body composition, bone, and lipid profiles. These findings have important implications
for understanding and preventing the consequences of changes in glycemic status on total
and regional body composition and areal bone mineral density. Conversion to prediabetes and T2D clearly show an accelerated decline in TB and appendicular LM and
T2D is associated with a greater decline of TB LM and greater gain in TB FM. Measures
of body composition in pre-diabetic and T2D patients should be added to standards of
medical care in diabetes. The prevention of pre-diabetes and T2D can be achieved
through lifestyle modifications (increased physical activity and intakes of fruit, vegetable,
and fiber, limit fat content, and weight reduction). These lifestyle modifications also may
improve body composition by reducing loss of LM.

